Baxter International (BAX (NYSE)) 10-Q 30 Jul 19 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Jul. 25, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Trading Symbol	BAX
Entity Registrant Name	BAXTER INTERNATIONAL INC
Entity Central Index Key	0000010456
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity File Number	1-4448
Entity Tax Identification Number	360781620
Entity Address, Address Line One	One Baxter Parkway
Entity Address, City or Town	Deerfield
Entity Address, State or Province	Illinois
Entity Address, Postal Zip Code	60015
City Area Code	224
Local Phone Number	948-2000
Entity Common Stock, Shares Outstanding		510,555,869

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 2,925	$ 1,832
Accounts and other current receivables, net	1,885	1,812
Inventories	1,757	1,653
Prepaid expenses and other	651	622
Total current assets	7,218	5,919
Property, plant and equipment, net	4,541	4,542
Goodwill	2,938	2,958
Other intangible assets, net	1,364	1,398
Operating lease right-of-use assets	588
Other non-current assets	895	824
Total assets	17,544	15,641
Current liabilities:
Short-term debt	2	2
Current maturities of long-term debt and finance lease obligations	2	2
Accounts payable and accrued liabilities	2,593	2,832
Total current liabilities	2,597	2,836
Long-term debt and finance lease obligations	5,157	3,473
Operating lease liabilities	490
Other non-current liabilities	1,464	1,516
Total liabilities	9,708	7,825
Equity:
Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2019 and 2018	683	683
Common stock in treasury, at cost, 173,275,586 shares in 2019 and 170,495,859 shares in 2018	(10,322)	(9,989)
Additional contributed capital	5,906	5,898
Retained earnings	16,184	15,626
Accumulated other comprehensive (loss) income	(4,639)	(4,424)
Total Baxter stockholders’ equity	7,812	7,794
Noncontrolling interests	24	22
Total equity	7,836	7,816
Total liabilities and equity	$ 17,544	$ 15,641

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Common stock, par value	$ 1	$ 1
Common stock, authorized	2,000,000,000	2,000,000,000
Common stock, issued	683,494,944	683,494,944
Treasury stock, shares	173,275,586	170,495,859

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Statement [Abstract]
Net sales	$ 2,840	$ 2,842	$ 5,472	$ 5,519
Cost of sales	1,681	1,603	3,233	3,166
Gross margin	1,159	1,239	2,239	2,353
Selling, general and administrative expenses	642	681	1,242	1,303
Research and development expenses	166	174	295	314
Other operating income, net	(4)		(37)	(80)
Operating income	355	384	739	816
Interest expense, net	20	11	38	23
Other income, net	(28)	(31)	(53)	(49)
Income before income taxes	363	404	754	842
Income tax expense	20	61	64	110
Net income	$ 343	$ 343	$ 690	$ 732
Net income per common share
Basic	$ 0.67	$ 0.64	$ 1.35	$ 1.36
Diluted	$ 0.66	$ 0.63	$ 1.33	$ 1.33
Weighted-average number of common shares outstanding
Basic	510	535	511	537
Diluted	519	547	520	549

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 343	$ 343	$ 690	$ 732
Other comprehensive (loss) income, net of tax:
Currency translation adjustments, net of tax (benefit) expense of ($4) and ($24) for the three months ended June 30, 2019 and 2018, respectively, and $2 and ($31) for the six months ended June 30, 2019 and 2018, respectively	(78)	(363)	(48)	(282)
Pension and other postretirement benefits, net of tax expense of $3 and $4 for the three months ended June 30, 2019 and 2018, respectively, and $6 and $17 for the six months ended June 30, 2019 and 2018, respectively	13	29	21	81
Hedging activities, net of tax (benefit) expense of ($3) and $2 for the three months ended June 30, 2019 and 2018, respectively, and ($8) and $3 for the six months ended June 30, 2019 and 2018, respectively	(12)	11	(27)	6
Total other comprehensive (loss) income, net of tax	(77)	(323)	(54)	(195)
Comprehensive income	$ 266	$ 20	$ 636	$ 537

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Comprehensive Income (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Statement Of Income And Comprehensive Income [Abstract]
Tax (benefit) expense on currency translation adjustments	$ (4)	$ (24)	$ 2	$ (31)
Tax expense on pension and other postretirement benefits	3	4	6	17
Tax (benefit) expense on hedging activities	$ (3)	$ 2	$ (8)	$ 3

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Changes in Equity (Unaudited) - USD ($) $ in Millions	Total	Common Stock	Common Stock in Treasury	Additional Contributed Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Parent	Noncontrolling Interest
Beginning of period at Dec. 31, 2017	$ 9,116	$ 683	$ (7,981)	$ 5,940	$ 14,483	$ (4,001)	$ 9,124	$ (8)
Beginning of period at Dec. 31, 2017		683,000,000
Beginning of period at Dec. 31, 2017			142,000,000
Adoption of new accounting standards	(19)				(16)	(3)	(19)
Net income	389				389		389
Other comprehensive income (loss)	128					128	128
Purchases of treasury stock	(522)		$ (522)				(522)
Purchases of treasury stock, shares			8,000,000
Stock issued under employee benefit plans and other	85		$ 149	(28)	(36)		85
Stock issued under employee benefit plans and other, shares			(3,000,000)
Dividends declared on common stock	(86)				(86)		(86)
Change in noncontrolling interests	2							2
End of period at Mar. 31, 2018	9,093	$ 683	$ (8,354)	5,912	14,734	(3,876)	9,099	(6)
End of period at Mar. 31, 2018		683,000,000
End of period at Mar. 31, 2018			147,000,000
Beginning of period at Dec. 31, 2017	9,116	$ 683	$ (7,981)	5,940	14,483	(4,001)	9,124	(8)
Beginning of period at Dec. 31, 2017		683,000,000
Beginning of period at Dec. 31, 2017			142,000,000
Net income	732
Other comprehensive income (loss)	$ (195)
Purchases of treasury stock, shares	11,500,000
End of period at Jun. 30, 2018	$ 8,869	$ 683	$ (8,485)	5,916	14,966	(4,199)	8,881	(12)
End of period at Jun. 30, 2018		683,000,000
End of period at Jun. 30, 2018			148,000,000
Beginning of period at Mar. 31, 2018	9,093	$ 683	$ (8,354)	5,912	14,734	(3,876)	9,099	(6)
Beginning of period at Mar. 31, 2018		683,000,000
Beginning of period at Mar. 31, 2018			147,000,000
Net income	343				343		343
Other comprehensive income (loss)	(323)					(323)	(323)
Purchases of treasury stock	(259)		$ (259)				(259)
Purchases of treasury stock, shares			3,000,000
Stock issued under employee benefit plans and other	123		$ 128	4	(9)		123
Stock issued under employee benefit plans and other, shares			(2,000,000)
Dividends declared on common stock	(102)				(102)		(102)
Change in noncontrolling interests	(6)							(6)
End of period at Jun. 30, 2018	8,869	$ 683	$ (8,485)	5,916	14,966	(4,199)	8,881	(12)
End of period at Jun. 30, 2018		683,000,000
End of period at Jun. 30, 2018			148,000,000
Beginning of period at Dec. 31, 2018	$ 7,816	$ 683	$ (9,989)	5,898	15,626	(4,424)	7,794	22
Beginning of period at Dec. 31, 2018	683,494,944	683,000,000
Beginning of period at Dec. 31, 2018	170,495,859		170,000,000
Adoption of new accounting standards					161	(161)
Net income	$ 347				347		347
Other comprehensive income (loss)	23					23	23
Purchases of treasury stock	(586)		$ (586)				(586)
Purchases of treasury stock, shares			8,000,000
Stock issued under employee benefit plans and other	166		$ 291	(59)	(66)		166
Stock issued under employee benefit plans and other, shares			(5,000,000)
Dividends declared on common stock	(98)				(98)		(98)
Change in noncontrolling interests	1							1
End of period at Mar. 31, 2019	7,669	$ 683	$ (10,284)	5,839	15,970	(4,562)	7,646	23
End of period at Mar. 31, 2019		683,000,000
End of period at Mar. 31, 2019			173,000,000
Beginning of period at Dec. 31, 2018	$ 7,816	$ 683	$ (9,989)	5,898	15,626	(4,424)	7,794	22
Beginning of period at Dec. 31, 2018	683,494,944	683,000,000
Beginning of period at Dec. 31, 2018	170,495,859		170,000,000
Net income	$ 690
Other comprehensive income (loss)	$ (54)
Purchases of treasury stock, shares	9,500,000
End of period at Jun. 30, 2019	$ 7,836	$ 683	$ (10,322)	5,906	16,184	(4,639)	7,812	24
End of period at Jun. 30, 2019	683,494,944	683,000,000
End of period at Jun. 30, 2019	173,275,586		173,000,000
Beginning of period at Mar. 31, 2019	$ 7,669	$ 683	$ (10,284)	5,839	15,970	(4,562)	7,646	23
Beginning of period at Mar. 31, 2019		683,000,000
Beginning of period at Mar. 31, 2019			173,000,000
Net income	343				343		343
Other comprehensive income (loss)	(77)					(77)	(77)
Purchases of treasury stock	(111)		$ (157)	46			(111)
Purchases of treasury stock, shares			2,000,000
Stock issued under employee benefit plans and other	123		$ 119	21	(17)		123
Stock issued under employee benefit plans and other, shares			(2,000,000)
Dividends declared on common stock	(112)				(112)		(112)
Change in noncontrolling interests	1							1
End of period at Jun. 30, 2019	$ 7,836	$ 683	$ (10,322)	$ 5,906	$ 16,184	$ (4,639)	$ 7,812	$ 24
End of period at Jun. 30, 2019	683,494,944	683,000,000
End of period at Jun. 30, 2019	173,275,586		173,000,000

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash flows from operations
Net income	$ 690	$ 732
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization	393	387
Deferred income taxes	(55)	(51)
Stock compensation	57	54
Net periodic pension benefit and other postretirement costs	7	21
Restructuring charges	77	33
Intangible asset impairment	31
Other	21	7
Changes in balance sheet items:
Accounts and other current receivables, net	(60)	43
Inventories	(91)	(134)
Accounts payable and accrued liabilities	(308)	(109)
Restructuring payments	(60)	(47)
Other	(85)	(84)
Cash flows from operations – continuing operations	617	852
Cash flows from operations – discontinued operations	(6)
Cash flows from operations	611	852
Cash flows from investing activities
Capital expenditures	(352)	(311)
Acquisitions and investments	(111)	(228)
Other investing activities, net	1
Cash flows from investing activities	(462)	(539)
Cash flows from financing activities
Issuances of debt	1,661
Cash dividends on common stock	(198)	(173)
Proceeds from stock issued under employee benefit plans	262	170
Purchases of treasury stock	(720)	(781)
Other financing activities, net	(37)	(24)
Cash flows from financing activities	968	(808)
Effect of foreign exchange rate changes on cash and cash equivalents	(24)	(42)
Increase (decrease) in cash and cash equivalents	1,093	(537)
Cash and cash equivalents at beginning of period	1,832	3,394
Cash and cash equivalents at end of period	2,925	2,857
Non-cash investing and financing activities
Decrease in liabilities for capital expenditures	47	$ 20
Decrease in liability for treasury stock purchases	$ 23

BASIS OF PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
BASIS OF PRESENTATION	1. BASIS OF PRESENTATION The unaudited interim condensed consolidated financial statements of Baxter International Inc. and its subsidiaries (we or our) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (GAAP) in the United States have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2018 ( 2018 Annual Report) In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented. All such adjustments, unless otherwise noted herein, are of a normal, recurring nature. The results of operations for the current interim period are not necessarily indicative of the results of operations to be expected for the full year. Certain reclassifications have been made to conform the prior period condensed consolidated statements to the current period presentation. New Accounting Standards Recently adopted accounting pronouncements As of January 1, 2019, we adopted Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842). Under this guidance, lessees are required to recognize a right-of-use asset and a lease liability on the balance sheet for all operating leases, other than those that meet the definition of a short-term lease. We adopted Topic 842 using the modified retrospective method. We elected the following practical expedients when assessing the transition impact: i) not to reassess whether any expired or existing contracts as of the adoption date are or contain leases; ii) not to reassess the lease classification for any expired or existing leases as of the adoption date; and iii) not to reassess initial direct costs for any existing leases as of the adoption date. The adjustment to record operating lease right-of-use assets and operating lease liabilities was $502 million as of January 1, 2019. The impact to the condensed consolidated statements of income was not material and there was no net impact to the condensed consolidated statements of cash flows. As of January 1, 2019, we adopted ASU No. 2017-12, Targeted Improvements to Accounting for Hedging Activities. The purpose of this ASU is to better align a company’s risk management activities and financial reporting for hedging relationships, simplify the hedge accounting requirements, and improve the disclosures of hedging arrangements. The adoption of this standard did not have a material impact on our condensed consolidated financial statements. As of January 1, 2019, we adopted ASU No. 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income (AOCI). As a result of the enactment of the U.S. Tax Cuts and Jobs Act of 2017 (the 2017 Tax Act), this guidance provides for a reclassification of certain tax effects from AOCI to retained earnings. The impact of the adoption of this standard was a $161 million increase to retained earnings.

ACQUISITIONS AND OTHER ARRANGEM

ACQUISITIONS AND OTHER ARRANGEMENTS	6 Months Ended
	Jun. 30, 2019
Business Combinations [Abstract]
ACQUISITIONS AND OTHER ARRANGEMENTS	2. ACQUISITIONS AND OTHER ARRANGEMENTS In the first quarter of 2019, we acquired the U.S. rights to multiple products for an aggregate purchase price of $94 million. The purchase prices were capitalized as developed-technology intangible assets and are being amortized over a weighted-average useful life of 10 years. Net sales related to these products in the first half of 2019 were not material. In July 2019, we acquired the U.S. rights to an additional product for $62 million. The purchase price will be capitalized as a developed-technology intangible asset in the quarter ending September 30, 2019 and will be amortized over its estimated useful life of 12 years.

SUPPLEMENTAL FINANCIAL INFORMAT

SUPPLEMENTAL FINANCIAL INFORMATION	6 Months Ended
	Jun. 30, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
SUPPLEMENTAL FINANCIAL INFORMATION	3. SUPPLEMENTAL FINANCIAL INFORMATION Interest Expense, Net Three months ended Six months ended June 30, June 30, (in millions) 2019 2018 2019 2018 Interest expense, net of capitalized interest $ 28 $ 24 $ 53 $ 46 Interest income (8 ) (13 ) (15 ) (23 ) Interest expense, net $ 20 $ 11 $ 38 $ 23 Other Income, Net Three months ended Six months ended June 30, June 30, (in millions) 2019 2018 2019 2018 Foreign exchange gains, net $ (17 ) $ (18 ) $ (22 ) $ (33 ) Pension and other postretirement benefits (15 ) (14 ) (31 ) (26 ) Other 4 1 — 10 Other income, net $ (28 ) $ (31 ) $ (53 ) $ (49 ) Inventories June 30, December 31, (in millions) 2019 2018 Raw materials $ 397 $ 363 Work in process 197 203 Finished goods 1,163 1,087 Inventories $ 1,757 $ 1,653 Property, Plant and Equipment, Net June 30, December 31, (in millions) 2019 2018 Property, plant and equipment, at cost $ 10,593 $ 10,327 Accumulated depreciation (6,052 ) (5,785 ) Property, plant and equipment, net $ 4,541 $ 4,542

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS, NET	6 Months Ended
	Jun. 30, 2019
Goodwill And Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS, NET	4. GOODWILL AND OTHER INTANGIBLE ASSETS, NET Goodwill The following is a reconciliation of goodwill by business segment. (in millions) Americas EMEA APAC Total Balance as of December 31, 2018 $ 2,351 $ 387 $ 220 $ 2,958 Adjustments — (4 ) — (4 ) Currency translation adjustments (13 ) (2 ) (1 ) (16 ) Balance as of June 30, 2019 $ 2,338 $ 381 $ 219 $ 2,938 As of June 30, 2019, there were no reductions in goodwill relating to impairment losses. Other intangible assets, net The following is a summary of our other intangible assets. (in millions) Developed technology, including patents Other amortized intangible assets Indefinite-lived intangible assets Total June 30, 2019 Gross other intangible assets $ 2,164 $ 450 $ 188 $ 2,802 Accumulated amortization (1,171 ) (267 ) — (1,438 ) Other intangible assets, net $ 993 $ 183 $ 188 $ 1,364 December 31, 2018 Gross other intangible assets $ 2,115 $ 451 $ 188 $ 2,754 Accumulated amortization (1,106 ) (250 ) — (1,356 ) Other intangible assets, net $ 1,009 $ 201 $ 188 $ 1,398 Intangible asset amortization expense was $45 million and $44 million for the three months ended June 30, 2019 and 2018, respectively, and $88 million and $85 million for the six months ended June 30, 2019 and 2018, respectively. For the three and six months ended June 30, 2019, we recognized a $31 million impairment charge related to a developed-technology intangible asset due to a decline in market expectations for the related product. The fair value of the intangible asset was measured using a discounted cash flow approach and the charge is classified within cost of sales in the accompanying condensed consolidated statements of income. We consider the fair value of the asset to be a Level 3 measurement due to the significant estimates and assumptions we used in establishing the estimated fair value.

FINANCIAL ARRANGEMENTS

FINANCIAL ARRANGEMENTS	6 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
FINANCIAL ARRANGEMENTS	5. FINANCING ARRANGEMENTS Debt Issuance In May 2019, we issued €750 million of 0.4% senior notes due in May 2024 and €750 million of 1.3% senior notes due in May 2029. We have designated these debt instruments as net investment hedges of our European operations. Refer to Note 15 for additional information. Short-term Debt In the second quarter of 2019, we repaid $795 million of commercial paper and other short-term borrowings that were outstanding as of March 31, 2019. No commercial paper was outstanding as of June 30, 2019 or December 31, 2018.

LEASES

LEASES	6 Months Ended
	Jun. 30, 2019
Leases [Abstract]
LEASES	6. LEASES Lessee Activity We have entered into operating and finance leases primarily for office, manufacturing and research and development (R&D) facilities, vehicles and equipment. Our leases have remaining terms from one to 25 years and some of those leases include options that provide us with the ability to extend the lease term for periods ranging from one to 12 years. Such options are included in the lease term when it is reasonably certain that the option will be exercised. Certain lease contracts include other services, such as operations and maintenance. For all asset classes, we have elected to apply a practical expedient to account for other services within lease contracts as components of the lease. We also have elected to apply a practical expedient for short-term leases whereby we do not recognize a lease liability and right-of-use asset for leases with a term of less than 12 months. We classify our leases as operating or finance at the lease commencement date. Finance leases are generally those leases for which we will pay substantially all of the underlying asset’s fair value or will use the asset for all or a major part of its economic life, including circumstances in which we will ultimately own the asset. All other leases are operating leases. For finance leases, we recognize interest expense using the effective interest method and we recognize amortization expense on the right-of-use asset over the shorter of the lease term or the useful life of the asset. For operating leases, we recognize lease cost on a straight-line basis over the term of the lease. Lease liabilities and right-of-use assets are recognized at the lease commencement date based on the present value of minimum lease payments over the lease term. We determine the present value of payments under a lease based on our incremental borrowing rate as of the lease commencement date. The incremental borrowing rate is equal to the rate of interest that we would have to pay to borrow on a collateralized basis over a similar term in an amount equal to the lease payments in a similar economic environment. For operating leases that commenced prior to our adoption of Topic 842, we measured the lease liabilities and right-of-use assets using our incremental borrowing rate as of January 1, 2019. There were no material lease transactions that we entered into but have not yet commenced as of June 30, 2019. The components of lease cost for the three and six months ended June 30, 2019 were: (in millions) Three months ended June 30, 2019 Six months ended June 30, 2019 Operating lease cost $ 29 $ 60 Finance lease cost Amortization of right-of-use assets 1 2 Interest on lease liabilities — 1 Variable lease cost 21 43 Lease cost $ 51 $ 106 The following table contains supplemental cash flow information related to leases for the six months ended June 30, 2019: (in millions) Six months ended June 30, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 60 Operating cash flows from finance leases 3 Financing cash flows from finance leases 1 Right-of-use operating lease assets obtained in exchange for lease obligations 140 Supplemental balance sheet information related to leases as of June 30, 2019 includes: (in millions) June 30, 2019 Operating leases Operating lease right-of-use assets $ 588 Accounts payable and accrued liabilities $ 98 Operating lease liabilities 490 Total operating lease liabilities $ 588 Finance leases Property, plant and equipment, at cost $ 81 Accumulated depreciation (27 ) Property, plant and equipment, net $ 54 Current maturities of long-term debt and finance lease obligations $ 1 Long-term debt and finance lease obligations 58 Total finance lease liabilities $ 59 Lease term and discount rates as of June 30, 2019 were: June 30, 2019 Weighted-average remaining lease term (years) Operating leases 10 Finance leases 15 Weighted-average discount rate Operating leases 2.8 % Finance leases 10.3 % Maturities of operating and finance lease liabilities as of June 30, 2019 were: (in millions) Finance Leases Operating Leases 2019 $ 4 $ 59 2020 8 99 2021 8 83 2022 8 70 2023 6 59 Thereafter 82 297 Total minimum lease payments 116 667 Less: imputed interest (57 ) (79 ) Present value of lease liabilities $ 59 $ 588 Future minimum lease payments as of December 31, 2018, as disclosed in our 2018 Annual Report, were: (in millions) Capital Leases Operating Leases 2019 $ 8 $ 122 2020 7 93 2021 7 86 2022 8 71 2023 6 64 Thereafter 88 210 Total minimum lease payments 124 $ 646 Less: imputed interest (62 ) Present value of lease liabilities $ 62 Lessor Activity We lease medical equipment, such as renal dialysis equipment and infusion pumps, to customers primarily in conjunction with arrangements to provide consumable medical products such as dialysis therapies, intravenous (IV) fluids and inhaled anesthetics. Certain of our equipment leases are classified as sales-type leases and the remainder are operating leases. The terms of the related contracts, including the proportion of fixed versus variable payments and any options to shorten or extend the lease term, vary by customer. We allocate revenue between equipment leases and medical products based on their standalone selling prices. The components of lease revenue for the three and six months ended June 30, 2019 were: (in millions) Three months ended June 30, 2019 Six months ended June 30, 2019 Sales-type lease revenue $ 5 $ 11 Operating lease revenue 15 30 Variable lease revenue 21 42 Total lease revenue $ 41 $ 83 The components of our net investment in sales-type leases as of June 30, 2019 were: (in millions) June 30, 2019 Minimum lease payments $ 86 Unguaranteed residual values 11 Net investment in leases $ 97 Our net investment in sales-type leases is classified as follows in the accompanying condensed consolidated balance sheets: (in millions) June 30, 2019 Accounts and other current receivables, net $ 36 Other non-current assets 61 Total $ 97 Maturities of sales-type and operating leases as of June 30, 2019 were: (in millions) Sales-type Leases Operating Leases 2019 $ 17 $ 24 2020 30 48 2021 24 48 2022 15 30 2023 8 16 Thereafter 2 7 Total minimum lease payments 96 $ 173 Less: imputed interest (10 ) Present value of minimum lease payments $ 86

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2019
Commitments And Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	7. COMMITMENTS AND CONTINGENCIES We are involved in product liability, patent, commercial, and other legal matters that arise in the normal course of our business. We record a liability when a loss is considered probable and the amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, and no amount within the range is a better estimate, the minimum amount in the range is accrued. If a loss is not probable or a probable loss cannot be reasonably estimated, no liability is recorded. As of June 30, 2019 and December 31, 2018, our total recorded reserves, including the environmental matters discussed below, with respect to legal matters were $49 million and $43 million, respectively, and there were no related receivables. We have established reserves for certain of the matters discussed below. We are not able to estimate the amount or range of any loss for certain contingencies for which there is no reserve or additional loss for matters already reserved. While our liability in connection with these claims cannot be estimated and the resolution thereof in any reporting period could have a significant impact on our results of operations and cash flows for that period, the outcome of these legal proceedings is not expected to have a material adverse effect on our consolidated financial position. While we believe that we have valid defenses in the matters set forth below, litigation is inherently uncertain, excessive verdicts do occur, and we may incur material judgments or enter into material settlements of claims. In addition to the matters described below, we remain subject to the risk of future administrative and legal actions. With respect to governmental and regulatory matters, these actions may lead to product recalls, injunctions, and other restrictions on our operations and monetary sanctions, including significant civil or criminal penalties. With respect to intellectual property, we may be exposed to significant litigation concerning the scope of our and others’ rights. Such litigation could result in a loss of patent protection or the ability to market products, which could lead to a significant loss of sales, or otherwise materially affect future results of operations. Environmental We are involved as a potentially responsible party (PRP) for environmental clean-up costs at six Superfund sites. Under the U.S. Superfund statute and many state laws, generators of hazardous waste sent to a disposal or recycling site are liable for site cleanup if contaminants from that property later leak into the environment. The laws generally provide that a PRP may be held jointly and severally liable for the costs of investigating and remediating the site. Separate from the Superfund cases noted above, we are involved in an ongoing voluntary environmental remediation associated with historic operations at our Irvine, California, United States facility. As of June 30, 2019 and December 31, 2018, our environmental reserves, which are measured on an undiscounted basis, were $20 million and $19 million, respectively. After considering these reserves, management is of the opinion that the outcome of these matters will not have a material adverse effect on our financial position or results of operations. General Litigation In November 2016, a purported antitrust class action complaint seeking monetary and injunctive relief was filed in the United States District Court for the Northern District of Illinois. The complaint alleges a conspiracy among manufacturers of IV solutions to restrict output and affect pricing in connection with a shortage of such solutions. Similar parallel actions subsequently were filed. In January 2017, a single consolidated complaint covering these matters was filed in the Northern District of Illinois. We filed a motion to dismiss the consolidated complaint in February 2017. The court granted our motion to dismiss the consolidated complaint without prejudice in July 2018. The plaintiffs filed an amended complaint on September 6, 2018. We filed a motion to dismiss the amended complaint on November 9, 2018. In April 2017, we became aware of a criminal investigation by the U.S. Department of Justice (DOJ), Antitrust Division and a federal grand jury in the United States District Court for the Eastern District of Pennsylvania. We and an employee received subpoenas seeking production of documents and testimony regarding the manufacturing, selling, pricing and shortages of IV solutions and containers (including saline solutions and certain other injectable medicines sold by us) and communications with competitors regarding the same. On November 30, 2018, the DOJ notified us that it had closed the investigation. The New York Attorney General has also requested that we provide information regarding business practices in the IV saline industry. We are cooperating with the New York Attorney General. Other As previously disclosed, in 2008 we recalled our heparin sodium injection products in the United States. Following the recall, more than 1,000 lawsuits alleging that plaintiffs suffered various reactions to a heparin contaminant, in some cases resulting in fatalities, were filed. In January 2019, the last of these cases was settled. In the first half of 2019, following the resolution of an insurance dispute, we received cash proceeds of $35 million for our allocation of the insurance proceeds under a settlement and cost-sharing agreement related to the defense of the heparin product liability cases. We recognized a $33 million gain in connection with the resolution of the dispute with the insurer that is classified within other operating income, net on the condensed consolidated statement of income for the six months ended June 30, 2019. In September 2017, Hurricane Maria caused damage to certain of our assets in Puerto Rico and disrupted operations. As previously disclosed, we realized $42 million of insurance recoveries in 2018 related to the damages and losses from that hurricane. In July 2019, an additional $40 million of claims were approved by our insurers and will be recognized in the quarter ending September 30, 2019. In December 2016, we received a civil investigative demand from the Commercial Litigation Branch of the U.S. DOJ primarily relating to contingent discount arrangements for, and other promotion of, our TISSEEL and ARTISS products. In April 2018, the DOJ filed a notice of its decision not to intervene and an underlying qui tam complaint ( U.S. ex rel. Andrew Capp v. Baxter

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	6 Months Ended
	Jun. 30, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
STOCKHOLDERS' EQUITY	8. STOCKHOLDERS’ EQUITY Cash Dividends Cash dividends declared per common share for the three and six months ended June 30, 2019 were $0.22 and $0.41, respectively. Cash dividends declared per common share for the three and six months ended June 30, 2018 were $0.19 and $0.35, respectively. Stock Repurchase Programs In July 2012, the Board of Directors authorized the repurchase of up to $2.0 billion of our common stock. The Board of Directors increased this authority by an additional $1.5 billion in each of November 2016 and February 2018 and by an additional $2.0 billion in November 2018. During the first half of 2019, we repurchased 9.5 million shares under this authority pursuant to Rule 10b5-1 plans and otherwise. During the first half of 2018, we repurchased 11.5 million shares pursuant to Rule 10b5-1 plans. We had $1.4 billion remaining available under the authorization as of June 30, 2019. In December 2018, we entered into a $300 million accelerated share repurchase agreement (ASR Agreement) with an investment bank. We funded the ASR Agreement with available cash. The ASR Agreement was executed pursuant to the 2012 Repurchase Authorization described above. Under the ASR Agreement, we received 3.6 million shares upon execution. Based on the volume-weighted average price of our common stock during the term of the ASR Agreement, we received an additional 0.6 million shares from the investment bank at settlement on May 7, 2019.

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE INCOME	6 Months Ended
	Jun. 30, 2019
Equity [Abstract]
ACCUMULATED OTHER COMPREHENSIVE INCOME	9. ACCUMULATED OTHER COMPREHENSIVE INCOME Comprehensive income includes all changes in stockholders’ equity that do not arise from transactions with shareholders, and consists of net income, currency translation adjustments (CTA), pension and other postretirement employee benefit (OPEB) plans, unrealized gains and losses on cash flow hedges and prior to 2018, unrealized gains and losses on available-for-sale equity securities. As a result of changes in accounting guidance related to available-for-sale equity securities, the unrealized gains and losses associated with these assets are no longer recognized in AOCI beginning January 1, 2018. The following table is a net-of-tax summary of the changes in AOCI by component for the six months ended June 30, 2019 and 2018. (in millions) CTA Pension and OPEB plans Hedging activities Total Gains (losses) Balance as of December 31, 2018 $ (3,474 ) $ (949 ) $ (1 ) $ (4,424 ) Adoption of new accounting standard 9 (169 ) (1 ) (161 ) Other comprehensive income before reclassifications (48 ) 8 (26 ) (66 ) Amounts reclassified from AOCI (a) — 13 (1 ) 12 Net other comprehensive income (loss) (48 ) 21 (27 ) (54 ) Balance as of June 30, 2019 $ (3,513 ) $ (1,097 ) $ (29 ) $ (4,639 ) (in millions) CTA Pension and OPEB plans Hedging activities Available- for-sale- equity securities Total Gains (losses) Balance as of December 31, 2017 $ (3,013 ) $ (981 ) $ (10 ) $ 3 $ (4,001 ) Adoption of new accounting standard — — — (3 ) (3 ) Other comprehensive income before reclassifications (282 ) 51 (1 ) — (232 ) Amounts reclassified from AOCI (a) — 30 7 — 37 Net other comprehensive income (loss) (282 ) 81 6 — (195 ) Balance as of June 30, 2018 $ (3,295 ) $ (900 ) $ (4 ) $ — $ (4,199 ) (a) See table below for details about these reclassifications. The following is a summary of the amounts reclassified from AOCI to net income during the three and six months ended June 30, 2019 and 2018. Amounts reclassified from AOCI (a) (in millions) Three months ended June 30, 2019 Six months ended June 30, 2019 Location of impact in income statement Amortization of pension and OPEB items Amortization of net losses and prior service costs or credits $ (7 ) $ (15 ) Other income, net (7 ) (15 ) Total before tax 1 2 Income tax expense $ (6 ) $ (13 ) Net of tax Gains on hedging activities Foreign exchange contracts $ 1 $ 1 Cost of sales 1 1 Total before tax — — Income tax expense $ 1 $ 1 Net of tax Total reclassifications for the period $ (5 ) $ (12 ) Total net of tax Amounts reclassified from AOCI (a) (in millions) Three months ended June 30, 2018 Six months ended June 30, 2018 Location of impact in income statement Amortization of pension and OPEB items Amortization of net losses and prior service costs or credits $ (18 ) $ (36 ) Other income, net (18 ) (36 ) Total before tax 3 6 Income tax expense $ (15 ) $ (30 ) Net of tax Losses on hedging activities Foreign exchange contracts $ (6 ) $ (10 ) Cost of sales (6 ) (10 ) Total before tax 2 3 Income tax expense $ (4 ) $ (7 ) Net of tax Total reclassifications for the period $ (19 ) $ (37 ) Total net of tax (a) Amounts in parentheses indicate reductions to net income. Refer to Note 12 for additional information regarding the amortization of pension and OPEB items and Note 15 for additional information regarding hedging activity.

REVENUES

REVENUES	6 Months Ended
	Jun. 30, 2019
Revenue From Contract With Customer [Abstract]
REVENUES	10. REVENUES Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in the contract. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Some of our contracts have multiple performance obligations. For contracts with multiple performance obligations, we allocate the contract’s transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract. Our global payment terms are typically between 30-90 days. The majority of our performance obligations are satisfied at a point in time. This includes sales of our broad portfolio of essentia l healthcare products across our geographic segments including acute and chronic dialysis therapies; sterile IV solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; and surgical hemostat and sealant products. For a majority of these sales, our performance obligation is satisfied upon delivery to the customer. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. To a lesser extent, in all of our segments, we enter into other types of contracts including contract manufacturing arrangements, equipment leases, and certain subscription software and licensing arrangements. We recognize revenue for these arrangements over time or at a point in time depending on our evaluation of when the customer obtains control of the promised goods or services. Revenue is recognized over time when we are creating or enhancing an asset that the customer controls as the asset is created or enhanced or our performance does not create an asset with an alternative use and we have an enforceable right to payment for performance completed. On June 30, 2019, we had $8.9 Significant Judgments Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for reserves related to rebates, product returns, sales discounts and wholesaler chargebacks. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are included in accounts and other current receivables, net and accounts payable and accrued liabilities on the condensed consolidated balance sheets. Management's estimates take into consideration historical experience, current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract using the expected value method. The amount of variable consideration included in the net sales price is limited to the amount that is probable not to result in a significant reversal in the amount of the cumulative revenue recognized in a future period. Revenue recognized during the three and six months ended June 30, 2019 and 2018 related to performance obligations satisfied in prior periods was not material. Contract Balances The timing of revenue recognition, billings and cash collections results in the recognition of trade accounts receivable, unbilled receivables, contract assets and customer advances and deposits (contract liabilities) on our condensed consolidated balance sheets. Net trade accounts receivable were $1.8 billion and $1.7 billion as of June 30, 2019 and December 31, 2018, respectively. For contract manufacturing arrangements, revenue is primarily recognized throughout the production cycle, which typically lasts up to 90 days, resulting in the recognition of contract assets until the related services are completed and the customers are billed. Additionally, for arrangements containing a performance obligation to deliver software that can be used with medical devices, we recognize revenue upon delivery of the software, which results in the recognition of contract assets when customers are billed over time, generally over one to five years. For certain bundled contracts, total contract revenue is allocated between equipment and consumable medical products. In conjunction with these arrangements, a contract asset is created, which represents the difference between the amount of equipment revenue recognized upon sale and the amount of consideration received from the customer. The contract asset is reclassified as accounts receivable as consumable medical products are provided and billed, generally over one to seven years. Our contract asset balances totaled $89 million as of June 30, 2019, of which $37 million related to contract manufacturing services, $40 million related to software sales and $12 million related to bundled equipment and consumable medical products contracts. Our contract asset balances totaled $80 million as of December 31, 2018, of which $33 million related to contract manufacturing services and $47 million related to software sales. Contract assets are presented within accounts and other receivables, net ($57 million and $50 million as of June 30, 2019 and December 31, 2018, respectively) and other non-current assets ($32 million and $30 million as of June 30, 2019 and December 31, 2018, respectively) in the accompanying condensed consolidated balance sheets. Contract liabilities as of June 30, 2019 and December 31, 2018 were not significant. Disaggregation of Net Sales The following tables disaggregate our net sales from contracts with customers by Global Business Unit (GBU) between the U.S. and international: Three months ended June 30, 2019 2018 (in millions) U.S. International Total U.S. International Total Renal Care 1 $ 196 $ 714 $ 910 $ 204 $ 727 $ 931 Medication Delivery 2 441 248 689 426 255 681 Pharmaceuticals 3 235 304 539 262 275 537 Clinical Nutrition 4 79 136 215 80 141 221 Advanced Surgery 5 143 89 232 118 86 204 Acute Therapies 6 44 89 133 42 87 129 Other 7 55 67 122 78 61 139 Total Baxter $ 1,193 $ 1,647 $ 2,840 $ 1,210 $ 1,632 $ 2,842 Six months ended June 30, 2019 2018 (in millions) U.S. International Total U.S. International Total Renal Care 1 $ 388 $ 1,373 $ 1,761 $ 400 $ 1,399 $ 1,799 Medication Delivery 2 847 476 1,323 862 495 1,357 Pharmaceuticals 3 467 581 1,048 505 528 1,033 Clinical Nutrition 4 156 264 420 163 281 444 Advanced Surgery 5 263 167 430 217 169 386 Acute Therapies 6 92 169 261 88 170 258 Other 7 100 129 229 122 120 242 Total Baxter $ 2,313 $ 3,159 $ 5,472 $ 2,357 $ 3,162 $ 5,519 1 Renal Care includes sales of our peritoneal dialysis (PD), hemodialysis (HD) and additional dialysis therapies and services. 2 Medication Delivery includes sales of our IV therapies, infusion pumps, administration sets and drug reconstitution devices. 3 Pharmaceuticals includes sales of our premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services. 4 Clinical Nutrition includes sales of our parenteral nutrition (PN) therapies and related products. 5 Advanced Surgery includes sales of our biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention. 6 Acute Therapies includes sales of our continuous renal replacement therapies (CRRT) and other organ support therapies focused in the intensive care unit (ICU). 7 Other primarily includes sales of contract manufacturing services from our pharmaceutical partnering business.

BUSINESS OPTIMIZATION CHARGES

BUSINESS OPTIMIZATION CHARGES	6 Months Ended
	Jun. 30, 2019
Restructuring And Related Activities [Abstract]
BUSINESS OPTIMIZATION CHARGES	11. BUSINESS OPTIMIZATION CHARGES Beginning in the second half of 2015, we have undertaken actions to transform our cost structure and enhance operational efficiency. These efforts include restructuring the organization, optimizing the manufacturing footprint, R&D operations and supply chain network, employing disciplined cost management, and centralizing and streamlining certain support functions. Through June 30, 2019, we have incurred cumulative pre-tax costs of $899 million related to these actions. The costs consisted primarily of employee termination, implementation costs and accelerated depreciation. We currently expect to incur additional pre-tax costs of approximately $70 million through the completion of these initiatives under our current program. These costs will primarily include employee termination costs, implementation costs, and accelerated depreciation. During the three and six months ended June 30, 2019 and 2018, we recorded the following charges related to business optimization programs. Three months ended Six months ended June 30, June 30, (in millions) 2019 2018 2019 2018 Restructuring charges $ 52 $ 21 $ 77 $ 33 Costs to implement business optimization programs 12 25 22 50 Accelerated depreciation 1 1 4 2 Total business optimization charges $ 65 $ 47 $ 103 $ 85 For segment reporting, business optimization charges are unallocated expenses. Costs to implement business optimization programs for the three and six months ended June 30, 2019 and 2018, respectively, consisted primarily of external consulting and transition costs, including employee compensation and related costs. The costs were generally included within cost of sales, selling, general and administrative (SG&A) expense and R&D expense. For the three and six months ended June 30, 2019 and 2018, respectively, we recognized accelerated depreciation, primarily associated with facilities to be closed. The costs were recorded within cost of sales and SG&A expense. During the three and six months ended June 30, 2019 and 2018, we recorded the following restructuring charges. Three months ended June 30, 2019 (in millions) COGS SG&A R&D Total Employee termination costs $ 6 $ 26 $ 17 $ 49 Contract termination and other costs 1 — — 1 Asset impairments 1 — 1 2 Total restructuring charges $ 8 $ 26 $ 18 $ 52 Three months ended June 30, 2018 (in millions) COGS SG&A R&D Total Employee termination costs $ 3 $ 8 $ 7 $ 18 Contract termination costs — 2 — 2 Asset impairments — 1 — 1 Total restructuring charges $ 3 $ 11 $ 7 $ 21 Six months ended June 30, 2019 (in millions) COGS SG&A R&D Total Employee termination costs $ 6 $ 25 $ 26 $ 57 Contract termination and other costs 8 — — 8 Asset impairments 10 1 1 12 Total restructuring charges $ 24 $ 26 $ 27 $ 77 Six months ended June 30, 2018 (in millions) COGS SG&A R&D Total Employee termination costs $ 4 $ 14 $ 10 $ 28 Contract termination costs — 2 — 2 Asset impairments 1 2 — 3 Total restructuring charges $ 5 $ 18 $ 10 $ 33 The following table summarizes activity in the reserves related to our restructuring initiatives. (in millions) Reserve as of December 31, 2018 $ 101 Charges 78 Reserve adjustments (13 ) Utilization (60 ) Currency translation 2 Reserve as of June 30, 2019 $ 108 Reserve adjustments primarily related to employee termination cost reserves established in prior periods. Substantially all of our restructuring reserves as of June 30, 2019 relate to employee termination costs, with the remaining reserves attributable to contract termination costs. The reserves are expected to be substantially utilized by the end of 2020.

PENSION AND OTHER POSTRETIREMEN

PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS	6 Months Ended
	Jun. 30, 2019
Compensation And Retirement Disclosure [Abstract]
PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS	12. PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS The following is a summary of net periodic benefit cost relating to our pension and OPEB plans. Three months ended Six months ended June 30, June 30, (in millions) 2019 2018 2019 2018 Pension benefits Service cost $ 19 $ 25 $ 38 $ 47 Interest cost 43 45 90 91 Expected return on plan assets (67 ) (79 ) (140 ) (157 ) Amortization of net losses and prior service costs 14 24 29 48 Net periodic pension benefit cost $ 9 $ 15 $ 17 $ 29 OPEB Interest cost $ 2 $ 2 $ 4 $ 4 Amortization of net loss and prior service credit (7 ) (6 ) (14 ) (12 ) Net periodic OPEB cost $ (5 ) $ (4 ) $ (10 ) $ (8 )

INCOME TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2019
Income Tax Disclosure [Abstract]
INCOME TAXES	13. INCOME TAXES Our effective income tax rate was 5.5% and 15.1% for the three months ended June 30, 2019 and 2018, respectively, and 8.5% and 13.1% for the six months ended June 30, 2019 and 2018, respectively. Our effective income tax rate can differ from the 21% U.S. Federal statutory rate due to a number of factors, including foreign rate differences, tax incentives, increases or decreases in valuation allowances and liabilities for uncertain tax positions and excess tax benefits on stock compensation awards. For the three and six months ended June 30, 2019, the difference between our effective income tax rate and the U.S. Federal statutory rate was primarily attributable to a tax benefit from the resolution of an uncertain tax position (UTP) as a result of a favorable ruling from the related taxing authority and excess tax benefits on stock compensation awards. For the three months ended June 30, 2018, the difference between our effective income tax rate and the U.S. Federal statutory rate was primarily driven by excess tax benefits on stock compensation awards, partially offset by the revaluation of Swedish net deferred tax assets due to legislation reducing the Swedish income tax rate. For the six months ended June 30, 2018, the difference between our effective income tax rate and the U.S. Federal statutory rate was primarily attributable to nontaxable income from the settlement of certain claims with the seller of the acquired operations of Claris Injectables Limited, excess tax benefits on stock compensation awards, an adjustment of provisional amounts related to U.S. tax reform, a reduction of a liability for a UTP as a result of a settlement with the related taxing authority and the reversal of a valuation allowance as a result of continued profit improvements. Partially offsetting the foregoing benefits was interest on the reserve for UTPs, the revaluation of Swedish net deferred tax assets and transfer pricing-related income tax accruals.

EARNINGS PER SHARE

EARNINGS PER SHARE	6 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
EARNINGS PER SHARE	14. EARNINGS PER SHARE The numerator for both basic and diluted earnings per share (EPS) is net income. The denominator for basic EPS is the weighted-average number of common shares outstanding during the period. The dilutive effect of outstanding stock options, restricted stock units (RSUs) and performance share units (PSUs) is reflected in the denominator for diluted EPS using the treasury stock method. The following table is a reconciliation of basic shares to diluted shares. Three months ended Six months ended June 30, June 30, (in millions) 2019 2018 2019 2018 Basic shares 510 535 511 537 Effect of dilutive securities 9 12 9 12 Diluted shares 519 547 520 549 The effect of dilutive securities included unexercised stock options, unvested RSUs and contingently issuable shares related to granted PSUs. The computation of diluted EPS excluded 4 million equity awards each for the three and six months ended June 30, 2019, respectively, and 4 million and 3 million equity awards for the three and six months ended June 30, 2018, respectively, because their inclusion would have had an anti-dilutive effect on diluted EPS.

DERIVATIVE INSTRUMENTS AND HEDG

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	6 Months Ended
	Jun. 30, 2019
Derivative Instruments And Hedging Activities Disclosure [Abstract]
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	15. DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES We operate on a global basis and are exposed to the risk that our earnings, cash flows and equity could be adversely impacted by fluctuations in foreign exchange and interest rates. Our hedging policy attempts to manage these risks to an acceptable level based on our judgment of the appropriate trade-off between risk, opportunity and costs. We are primarily exposed to foreign exchange risk with respect to recognized assets and liabilities, forecasted transactions and net assets denominated in the Euro, British Pound, Chinese Yuan, Korean Won, Australian Dollar, Canadian Dollar, Japanese Yen, Colombian Peso, Brazilian Real, Mexican Peso and Swedish Krona. We manage our foreign currency exposures on a consolidated basis, which allows us to net exposures and take advantage of any natural offsets. In addition, we use derivative and nonderivative instruments to further reduce the net exposure to foreign exchange risk. Gains and losses on the hedging instruments offset losses and gains on the hedged transactions and reduce the earnings and equity volatility resulting from changes in foreign exchange rates. Financial market and currency volatility may limit our ability to cost-effectively hedge these exposures. We are also exposed to the risk that our earnings and cash flows could be adversely impacted by fluctuations in interest rates. Our policy is to manage interest costs using a mix of fixed- and floating-rate debt that we believe is appropriate. To manage this mix in a cost-efficient manner, we periodically enter into interest rate swaps in which we agree to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional amount. We do not hold any instruments for trading purposes and none of our outstanding derivative instruments contain credit-risk-related contingent features. All derivative instruments are recognized as either assets or liabilities at fair value in the condensed consolidated balance sheets and are classified as short-term or long-term based on the scheduled maturity of the instrument. We designate certain of our hedging instruments as cash flow, fair value, or net investment hedges. Cash Flow Hedges We may use options, including collars and purchased options, forwards and cross-currency swaps to hedge the foreign exchange risk to earnings relating to forecasted transactions and recognized assets and liabilities. We periodically use treasury rate locks to hedge the risk to earnings associated with movements in interest rates relating to anticipated issuances of debt. For each derivative instrument that is designated and effective as a cash flow hedge, the gain or loss on the derivative is recorded in AOCI and then recognized in earnings consistent with the underlying hedged item. Option premiums or net premiums paid are initially recorded as assets and reclassified to other comprehensive income (OCI) over the life of the option, and then recognized in earnings consistent with the underlying hedged item. Cash flow hedges are classified in net sales, cost of sales and interest expense , net , and are primarily related to forecasted third-party sales denominated in foreign currencies, forecasted intercompany sales denominated in foreign currencies, and anticipated issuances of debt, respectively. The notional amounts of foreign exchange contracts designated as cash flow hedges were $629 million and $775 million as of June 30, 2019 and December 31, 2018, respectively. The total notional amounts of interest rate contracts designated as cash flow hedges were $300 million and $150 million as of June 30, 2019 and December 31, 2018, respectively. The maximum term over which we have cash flow hedge contracts in place related to forecasted transactions at June 30, 2019 is 18 months for foreign exchange contracts and 30 years for interest rate contracts. Fair Value Hedges We periodically use interest rate swaps to convert a portion of our fixed-rate debt into variable-rate debt. These instruments hedge our earnings from changes in the fair value of debt due to fluctuations in the designated benchmark interest rate. For each derivative instrument that is designated and effective as a fair value hedge, the gain or loss on the derivative is recognized immediately to earnings, and offsets the loss or gain on the underlying hedged item. Fair value hedges are classified in interest expense, net, as they hedge the interest rate risk associated with certain of our fixed-rate debt. There were no outstanding interest rate swap contracts designated as fair value hedges as of June 30, 2019 and December 31, 2018. Net Investment Hedges In May 2017, we issued €600 million of senior notes due May 2025. In May 2019, we issued €750 million of senior notes due May 2024 and €750 million of senior notes due May 2029. We have designated these debt obligations as hedges of our net investment in our European operations and, as a result, mark to spot rate adjustments of the outstanding debt balances have been and will be recorded as a component of AOCI. As of June 30, 2019, we had an accumulated pre-tax unrealized translation loss in AOCI of $69 million related to the Euro-denominated senior notes. In May 2019, we entered into forward contracts designated as net investment hedges to reduce exposure to changes in currency rates on €1.2 billion of our net investment in our European operations. Those hedges were entered into in advance of the issuance of our senior notes mentioned above, were settled in the second quarter of 2019 and resulted in an insignificant loss. Dedesignations If it is determined that a derivative or nonderivative hedging instrument is no longer highly effective as a hedge, we discontinue hedge accounting prospectively. If we remove the cash flow hedge designation because the hedged forecasted transactions are no longer probable of occurring, any gains or losses are immediately reclassified from AOCI to earnings. Gains or losses relating to terminations of effective cash flow hedges in which the forecasted transactions are still probable of occurring are deferred and recognized consistent with the loss or income recognition of the underlying hedged items. There were no hedge dedesignations in the first six months of 2019 or 2018 resulting from changes in our assessment of the probability that the hedged forecasted transactions would occur. If we terminate a fair value hedge, an amount equal to the cumulative fair value adjustment to the hedged items at the date of termination is amortized to earnings over the remaining term of the hedged item. There were no fair value hedges terminated during the first six months of 2019 and 2018. If we terminate a net investment hedge, any gain or loss recognized in AOCI is not reclassified to earnings until we sell, liquidate, or deconsolidate the foreign investments that were being hedged. In the second quarter of 2019, we dedesignated €1.2 billion of forward contracts designated as a net investment hedge of our European operations. Undesignated Derivative Instruments We use forward contracts to hedge earnings from the effects of foreign exchange relating to certain of our intercompany and third-party receivables and payables denominated in a foreign currency. These derivative instruments are generally not formally designated as hedges and the terms of these instruments generally do not exceed one month. The total notional amount of undesignated derivative instruments was $494 million as of June 30, 2019 and $485 million as of December 31, 2018. Gains and Losses on Derivative Instruments The following tables summarize the income statement locations and gains and losses on our derivative instruments for the three months ended June 30, 2019 and 2018. Gain (loss) recognized in OCI Location of gain (loss) Gain (loss) reclassified from AOCI into income (in millions) 2019 2018 in income statement 2019 2018 Cash flow hedges Interest rate contracts $ (23 ) $ — Interest expense, net $ — $ — Foreign exchange contracts 9 7 Cost of sales 1 (6 ) Net investment hedges (36 ) 38 Other income, net — — Total $ (50 ) $ 45 $ 1 $ (6 ) Gain (loss) recognized in income (in millions) Location of gain (loss) in income statement 2019 2018 Undesignated derivative instruments Foreign exchange contracts Other income, net $ 3 $ 6 The following tables summarize the income statement locations and gains and losses on our derivative instruments for the six months ended June 30, 2019 and 2018. Gain (loss) recognized in OCI Location of gain (loss) Gain (loss) reclassified from AOCI into income (in millions) 2019 2018 in income statement 2019 2018 Cash flow hedges Interest rate contracts $ (34 ) $ — Interest expense, net $ — $ — Foreign exchange contracts — (2 ) Cost of sales 1 (10 ) Net investment hedges (22 ) 17 Other income, net — — Total $ (56 ) $ 15 $ 1 $ (10 ) Gain (loss) recognized in income (in millions) Location of gain (loss) in income statement 2019 2018 Fair value hedges Interest rate contracts Interest expense, net $ — $ (4 ) Undesignated derivative instruments Foreign exchange contracts Other income, net $ (6 ) $ (11 ) For our fair value hedges, an equal and offsetting gain of $4 million was recognized in interest expense, net as an adjustment to the underlying hedged item, fixed-rate debt, in the second quarter and first half of 2018. As of June 30, 2019, $13 million of deferred, net after-tax gains on derivative instruments included in AOCI are expected to be recognized in earnings during the next 12 months, coinciding with when the hedged items are expected to impact earnings. Fair Values of Derivative Instruments The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of June 30, 2019. Derivatives in asset positions Derivatives in liability positions (in millions) Balance sheet location Fair value Balance sheet location Fair value Derivative instruments designated as hedges Interest rate contracts Other non-current assets $ — Other non-current liabilities $ 37 Foreign exchange contracts Prepaid expenses and other 20 Accounts payable and accrued liabilities 1 Foreign exchange contracts Other non-current assets 1 Other non-current liabilities — Total derivative instruments designated as hedges 21 38 Undesignated derivative instruments Foreign exchange contracts Prepaid expenses and other — Accounts payable and accrued liabilities — Total derivative instruments $ 21 $ 38 The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of December 31, 2018. Derivatives in asset positions Derivatives in liability positions (in millions) Balance sheet location Fair value Balance sheet location Fair value Derivative instruments designated as hedges Interest rate contracts Other non-current assets $ — Other non-current liabilities $ 3 Foreign exchange contracts Prepaid expenses and other 22 Accounts payable and accrued liabilities 1 Foreign exchange contracts Other non-current assets 1 Other non-current liabilities — Total derivative instruments designated as hedges 23 4 Undesignated derivative instruments Foreign exchange contracts Prepaid expenses and other — Accounts payable and accrued liabilities 1 Total derivative instruments $ 23 $ 5 While some of our derivatives are subject to master netting arrangements, we present our assets and liabilities related to derivative instruments on a gross basis within the condensed consolidated balance sheets. Additionally, we are not required to post collateral for any of our outstanding derivatives. The following table provides information on our derivative positions as if they were presented on a net basis, allowing for the right of offset by counterparty. June 30, 2019 December 31, 2018 (in millions) Asset Liability Asset Liability Gross amounts recognized in the consolidated balance sheet $ 21 $ 38 $ 23 $ 5 Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet (1 ) (1 ) (5 ) (5 ) Total $ 20 $ 37 $ 18 $ — The following table presents the amounts recorded on the condensed consolidated balance sheet related to fair value hedges: Carrying amount of hedged item Cumulative amount of fair value hedging adjustment included in the carrying amount of the hedged item (a) (in millions) Balance as of June 30, 2019 Balance as of December 31, 2018 Balance as of June 30, 2019 Balance as of December 31, 2018 Long-term debt $ 103 $ 103 $ 6 $ 7 (a) These fair value hedges were terminated prior to December 31, 2018.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	16. FAIR VALUE MEASUREMENTS The following tables summarize our financial instruments that are measured at fair value on a recurring basis. Basis of fair value measurement (in millions) Balance as of June 30, 2019 Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Assets Foreign exchange contracts $ 21 $ — $ 21 $ — Marketable equity securities 4 4 — — Total $ 25 $ 4 $ 21 $ — Liabilities Foreign exchange contracts $ 1 $ — $ 1 $ — Interest rate contracts 37 — 37 — Contingent payments related to acquisitions 27 — — 27 Total $ 65 $ — $ 38 $ 27 Basis of fair value measurement (in millions) Balance as of December 31, 2018 Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Assets Foreign exchange contracts $ 23 $ — $ 23 $ — Marketable equity securities 3 3 — — Total $ 26 $ 3 $ 23 $ — Liabilities Foreign exchange contracts $ 2 $ — $ 2 $ — Interest rate contracts 3 — 3 — Contingent payments related to acquisitions 32 — — 32 Total $ 37 $ — $ 5 $ 32 As of June 30, 2019 and December 31, 2018, cash and cash equivalents of $2.9 billion and $1.8 billion, respectively, included money market funds of approximately $1.5 billion and $169 million, respectively, which are considered Level 2 in the fair value hierarchy. For assets that are measured using quoted prices in active markets, the fair value is the published market price per unit multiplied by the number of units held, without consideration of transaction costs. The majority of the derivatives entered into by us are valued using internal valuation techniques as no quoted market prices exist for such instruments. The principal techniques used to value these instruments are discounted cash flow and Black-Scholes models. The key inputs, which are considered observable and vary depending on the type of derivative, include contractual terms, interest rate yield curves, foreign exchange rates and volatility. Contingent payments related to acquisitions, which consist of milestone payments and sales-based payments, are valued using discounted cash flow techniques. The fair value of milestone payments reflects management’s expectations of probability of payment, and increases as the probability of payment increases or the expected timing of payments is accelerated. The fair value of sales-based payments is based upon probability-weighted future revenue estimates, and increases as revenue estimates increase, probability weighting of higher revenue scenarios increases or the expected timing of payment is accelerated. The following table is a reconciliation of the fair value measurements that use significant unobservable inputs (Level 3), which consist of contingent payments related to acquisitions. Three months ended June 30, Six months ended June 30, (in millions) 2019 2018 2019 2018 Fair value at beginning of period $ 31 $ 23 $ 32 $ 9 Additions — — — 14 Change in fair value recognized in earnings (4 ) — (4 ) — Payments — — (1 ) — Fair value at end of period $ 27 $ 23 $ 27 $ 23 Equity investments not measured at fair value are comprised of other equity investments without readily determinable fair values and were $39 million at June 30, 2019 and $41 million at December 31, 2018. These amounts are included in Other non-current assets. Fair Values of Financial Instruments Not Measured at Fair Value In addition to the financial instruments that we are required to recognize at fair value in the condensed consolidated balance sheets, we have certain financial instruments that are recognized at amortized cost or some basis other than fair value. For these financial instruments, the following table provides the values recognized in the condensed consolidated balance sheets and the estimated fair values as of June 30, 2019 and December 31, 2018. Book values Fair values (a) (in millions) 2019 2018 2019 2018 Liabilities Short-term debt $ 2 $ 2 $ 2 $ 2 Current maturities of long-term debt and finance lease obligations 2 2 2 2 Long-term debt and finance lease obligations 5,157 3,473 5,440 3,460 (a) These fair value amounts are classified as Level 2 within the fair value hierarchy as they are estimated based on observable inputs. The carrying value of short-term debt approximates its fair value due to the short-term maturities of the obligations. The estimated fair values of current and long-term debt were computed by multiplying price by the notional amount of the respective debt instruments. Price is calculated using the stated terms of the respective debt instrument and yield curves commensurate with our credit risk. The carrying values of other financial instruments approximate their fair values due to the short-term maturities of most of those assets and liabilities.

SEGMENT INFORMATION

SEGMENT INFORMATION	6 Months Ended
	Jun. 30, 2019
Segment Reporting [Abstract]
SEGMENT INFORMATION	17. SEGMENT INFORMATION We manage our business based on three geographical segments: Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia Pacific). Our segments provide a broad portfolio of essential healthcare products, including acute and chronic dialysis therapies; sterile IV solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; and surgical hemostat and sealant products. We use operating income on a segment basis to make resource allocation decisions and assess the ongoing performance of our business segments. Intersegment sales are eliminated in consolidation. Certain items are maintained at Corporate and are not allocated to a segment. They primarily include the majority of the foreign currency hedging activities, corporate headquarters costs, certain R&D costs, certain GBU support costs, stock compensation expense, certain employee benefit plan costs as well as certain gains, losses, and other charges (such as business optimization, acquisition and integration costs, intangible asset amortization and asset impairments). Our chief operating decision maker does not receive any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Financial information for our segments is as follows. Three months ended Six months ended June 30, June 30, (in millions) 2019 2018 2019 2018 Net sales Americas $ 1,520 $ 1,525 $ 2,928 $ 2,967 EMEA 744 758 1,449 1,482 APAC 576 559 1,095 1,070 Total net sales $ 2,840 $ 2,842 $ 5,472 $ 5,519 Operating Income Americas $ 584 $ 619 $ 1,121 $ 1,185 EMEA 162 162 307 313 APAC 137 131 258 248 Total segment operating income $ 883 $ 912 $ 1,686 $ 1,746 The following is a reconciliation of segment operating income to income before income taxes per the condensed consolidated statements of income. Three months ended Six months ended June 30, June 30, (in millions) 2019 2018 2019 2018 Total segment operating income $ 883 $ 912 $ 1,686 $ 1,746 Corporate and other (528 ) (528 ) (947 ) (930 ) Total operating income 355 384 739 816 Net interest expense 20 11 38 23 Other income, net (28 ) (31 ) (53 ) (49 ) Income before income taxes $ 363 $ 404 $ 754 $ 842 Refer to Note 10 for additional information on Net Sales by GBU.

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation	The unaudited interim condensed consolidated financial statements of Baxter International Inc. and its subsidiaries (we or our) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (GAAP) in the United States have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2018 ( 2018 Annual Report) In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented. All such adjustments, unless otherwise noted herein, are of a normal, recurring nature. The results of operations for the current interim period are not necessarily indicative of the results of operations to be expected for the full year. Certain reclassifications have been made to conform the prior period condensed consolidated statements to the current period presentation.
New Accounting Standards	New Accounting Standards Recently adopted accounting pronouncements As of January 1, 2019, we adopted Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842). Under this guidance, lessees are required to recognize a right-of-use asset and a lease liability on the balance sheet for all operating leases, other than those that meet the definition of a short-term lease. We adopted Topic 842 using the modified retrospective method. We elected the following practical expedients when assessing the transition impact: i) not to reassess whether any expired or existing contracts as of the adoption date are or contain leases; ii) not to reassess the lease classification for any expired or existing leases as of the adoption date; and iii) not to reassess initial direct costs for any existing leases as of the adoption date. The adjustment to record operating lease right-of-use assets and operating lease liabilities was $502 million as of January 1, 2019. The impact to the condensed consolidated statements of income was not material and there was no net impact to the condensed consolidated statements of cash flows. As of January 1, 2019, we adopted ASU No. 2017-12, Targeted Improvements to Accounting for Hedging Activities. The purpose of this ASU is to better align a company’s risk management activities and financial reporting for hedging relationships, simplify the hedge accounting requirements, and improve the disclosures of hedging arrangements. The adoption of this standard did not have a material impact on our condensed consolidated financial statements. As of January 1, 2019, we adopted ASU No. 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income (AOCI). As a result of the enactment of the U.S. Tax Cuts and Jobs Act of 2017 (the 2017 Tax Act), this guidance provides for a reclassification of certain tax effects from AOCI to retained earnings. The impact of the adoption of this standard was a $161 million increase to retained earnings.

SUPPLEMENTAL FINANCIAL INFORM_2

SUPPLEMENTAL FINANCIAL INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Interest Expense, Net	Interest Expense, Net Three months ended Six months ended June 30, June 30, (in millions) 2019 2018 2019 2018 Interest expense, net of capitalized interest $ 28 $ 24 $ 53 $ 46 Interest income (8 ) (13 ) (15 ) (23 ) Interest expense, net $ 20 $ 11 $ 38 $ 23
Other Income, Net	Other Income, Net Three months ended Six months ended June 30, June 30, (in millions) 2019 2018 2019 2018 Foreign exchange gains, net $ (17 ) $ (18 ) $ (22 ) $ (33 ) Pension and other postretirement benefits (15 ) (14 ) (31 ) (26 ) Other 4 1 — 10 Other income, net $ (28 ) $ (31 ) $ (53 ) $ (49 )
Inventories	Inventories June 30, December 31, (in millions) 2019 2018 Raw materials $ 397 $ 363 Work in process 197 203 Finished goods 1,163 1,087 Inventories $ 1,757 $ 1,653
Property, Plant and Equipment, Net	Property, Plant and Equipment, Net June 30, December 31, (in millions) 2019 2018 Property, plant and equipment, at cost $ 10,593 $ 10,327 Accumulated depreciation (6,052 ) (5,785 ) Property, plant and equipment, net $ 4,541 $ 4,542

GOODWILL AND OTHER INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)	6 Months Ended
	Jun. 30, 2019
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	The following is a reconciliation of goodwill by business segment. (in millions) Americas EMEA APAC Total Balance as of December 31, 2018 $ 2,351 $ 387 $ 220 $ 2,958 Adjustments — (4 ) — (4 ) Currency translation adjustments (13 ) (2 ) (1 ) (16 ) Balance as of June 30, 2019 $ 2,338 $ 381 $ 219 $ 2,938
Other Intangible Assets, Net	The following is a summary of our other intangible assets. (in millions) Developed technology, including patents Other amortized intangible assets Indefinite-lived intangible assets Total June 30, 2019 Gross other intangible assets $ 2,164 $ 450 $ 188 $ 2,802 Accumulated amortization (1,171 ) (267 ) — (1,438 ) Other intangible assets, net $ 993 $ 183 $ 188 $ 1,364 December 31, 2018 Gross other intangible assets $ 2,115 $ 451 $ 188 $ 2,754 Accumulated amortization (1,106 ) (250 ) — (1,356 ) Other intangible assets, net $ 1,009 $ 201 $ 188 $ 1,398

LEASES (Tables)

LEASES (Tables)	6 Months Ended
	Jun. 30, 2019
Leases [Abstract]
Components of Lease Cost	The components of lease cost for the three and six months ended June 30, 2019 were: (in millions) Three months ended June 30, 2019 Six months ended June 30, 2019 Operating lease cost $ 29 $ 60 Finance lease cost Amortization of right-of-use assets 1 2 Interest on lease liabilities — 1 Variable lease cost 21 43 Lease cost $ 51 $ 106
Supplemental Cash Flow Information Related to Leases	The following table contains supplemental cash flow information related to leases for the six months ended June 30, 2019: (in millions) Six months ended June 30, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 60 Operating cash flows from finance leases 3 Financing cash flows from finance leases 1 Right-of-use operating lease assets obtained in exchange for lease obligations 140
Supplemental Balance Sheet Information Related to Leases	Supplemental balance sheet information related to leases as of June 30, 2019 includes: (in millions) June 30, 2019 Operating leases Operating lease right-of-use assets $ 588 Accounts payable and accrued liabilities $ 98 Operating lease liabilities 490 Total operating lease liabilities $ 588 Finance leases Property, plant and equipment, at cost $ 81 Accumulated depreciation (27 ) Property, plant and equipment, net $ 54 Current maturities of long-term debt and finance lease obligations $ 1 Long-term debt and finance lease obligations 58 Total finance lease liabilities $ 59
Schedule of Lease Term and Discount Rates	Lease term and discount rates as of June 30, 2019 were: June 30, 2019 Weighted-average remaining lease term (years) Operating leases 10 Finance leases 15 Weighted-average discount rate Operating leases 2.8 % Finance leases 10.3 %
Maturities of Operating and Finance Lease Liabilities	Maturities of operating and finance lease liabilities as of June 30, 2019 were: (in millions) Finance Leases Operating Leases 2019 $ 4 $ 59 2020 8 99 2021 8 83 2022 8 70 2023 6 59 Thereafter 82 297 Total minimum lease payments 116 667 Less: imputed interest (57 ) (79 ) Present value of lease liabilities $ 59 $ 588
Schedule of Future Minimum Lease Payments	Future minimum lease payments as of December 31, 2018, as disclosed in our 2018 Annual Report, were: (in millions) Capital Leases Operating Leases 2019 $ 8 $ 122 2020 7 93 2021 7 86 2022 8 71 2023 6 64 Thereafter 88 210 Total minimum lease payments 124 $ 646 Less: imputed interest (62 ) Present value of lease liabilities $ 62
Components of Lease Revenue	The components of lease revenue for the three and six months ended June 30, 2019 were: (in millions) Three months ended June 30, 2019 Six months ended June 30, 2019 Sales-type lease revenue $ 5 $ 11 Operating lease revenue 15 30 Variable lease revenue 21 42 Total lease revenue $ 41 $ 83
Components of Net Investment In Sales-type Leases	The components of our net investment in sales-type leases as of June 30, 2019 were: (in millions) June 30, 2019 Minimum lease payments $ 86 Unguaranteed residual values 11 Net investment in leases $ 97
Net Investment in Sales Type Leases Classified in Accompanying Condensed Consolidated Balance Sheets	Our net investment in sales-type leases is classified as follows in the accompanying condensed consolidated balance sheets: (in millions) June 30, 2019 Accounts and other current receivables, net $ 36 Other non-current assets 61 Total $ 97
Maturities of Sales-type and Operating Leases	Maturities of sales-type and operating leases as of June 30, 2019 were: (in millions) Sales-type Leases Operating Leases 2019 $ 17 $ 24 2020 30 48 2021 24 48 2022 15 30 2023 8 16 Thereafter 2 7 Total minimum lease payments 96 $ 173 Less: imputed interest (10 ) Present value of minimum lease payments $ 86

ACCUMULATED OTHER COMPREHENSI_2

ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)	6 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Summary of Changes in AOCI by Component	The following table is a net-of-tax summary of the changes in AOCI by component for the six months ended June 30, 2019 and 2018. (in millions) CTA Pension and OPEB plans Hedging activities Total Gains (losses) Balance as of December 31, 2018 $ (3,474 ) $ (949 ) $ (1 ) $ (4,424 ) Adoption of new accounting standard 9 (169 ) (1 ) (161 ) Other comprehensive income before reclassifications (48 ) 8 (26 ) (66 ) Amounts reclassified from AOCI (a) — 13 (1 ) 12 Net other comprehensive income (loss) (48 ) 21 (27 ) (54 ) Balance as of June 30, 2019 $ (3,513 ) $ (1,097 ) $ (29 ) $ (4,639 ) (in millions) CTA Pension and OPEB plans Hedging activities Available- for-sale- equity securities Total Gains (losses) Balance as of December 31, 2017 $ (3,013 ) $ (981 ) $ (10 ) $ 3 $ (4,001 ) Adoption of new accounting standard — — — (3 ) (3 ) Other comprehensive income before reclassifications (282 ) 51 (1 ) — (232 ) Amounts reclassified from AOCI (a) — 30 7 — 37 Net other comprehensive income (loss) (282 ) 81 6 — (195 ) Balance as of June 30, 2018 $ (3,295 ) $ (900 ) $ (4 ) $ — $ (4,199 ) (a) See table below for details about these reclassifications.
Summary of Reclassification from AOCI to Net Income	The following is a summary of the amounts reclassified from AOCI to net income during the three and six months ended June 30, 2019 and 2018. Amounts reclassified from AOCI (a) (in millions) Three months ended June 30, 2019 Six months ended June 30, 2019 Location of impact in income statement Amortization of pension and OPEB items Amortization of net losses and prior service costs or credits $ (7 ) $ (15 ) Other income, net (7 ) (15 ) Total before tax 1 2 Income tax expense $ (6 ) $ (13 ) Net of tax Gains on hedging activities Foreign exchange contracts $ 1 $ 1 Cost of sales 1 1 Total before tax — — Income tax expense $ 1 $ 1 Net of tax Total reclassifications for the period $ (5 ) $ (12 ) Total net of tax Amounts reclassified from AOCI (a) (in millions) Three months ended June 30, 2018 Six months ended June 30, 2018 Location of impact in income statement Amortization of pension and OPEB items Amortization of net losses and prior service costs or credits $ (18 ) $ (36 ) Other income, net (18 ) (36 ) Total before tax 3 6 Income tax expense $ (15 ) $ (30 ) Net of tax Losses on hedging activities Foreign exchange contracts $ (6 ) $ (10 ) Cost of sales (6 ) (10 ) Total before tax 2 3 Income tax expense $ (4 ) $ (7 ) Net of tax Total reclassifications for the period $ (19 ) $ (37 ) Total net of tax (a) Amounts in parentheses indicate reductions to net income.

REVENUES (Tables)

REVENUES (Tables)	6 Months Ended
	Jun. 30, 2019
Revenue From Contract With Customer [Abstract]
Net Sales from Contracts with Customers by Global Business Unit	The following tables disaggregate our net sales from contracts with customers by Global Business Unit (GBU) between the U.S. and international: Three months ended June 30, 2019 2018 (in millions) U.S. International Total U.S. International Total Renal Care 1 $ 196 $ 714 $ 910 $ 204 $ 727 $ 931 Medication Delivery 2 441 248 689 426 255 681 Pharmaceuticals 3 235 304 539 262 275 537 Clinical Nutrition 4 79 136 215 80 141 221 Advanced Surgery 5 143 89 232 118 86 204 Acute Therapies 6 44 89 133 42 87 129 Other 7 55 67 122 78 61 139 Total Baxter $ 1,193 $ 1,647 $ 2,840 $ 1,210 $ 1,632 $ 2,842 Six months ended June 30, 2019 2018 (in millions) U.S. International Total U.S. International Total Renal Care 1 $ 388 $ 1,373 $ 1,761 $ 400 $ 1,399 $ 1,799 Medication Delivery 2 847 476 1,323 862 495 1,357 Pharmaceuticals 3 467 581 1,048 505 528 1,033 Clinical Nutrition 4 156 264 420 163 281 444 Advanced Surgery 5 263 167 430 217 169 386 Acute Therapies 6 92 169 261 88 170 258 Other 7 100 129 229 122 120 242 Total Baxter $ 2,313 $ 3,159 $ 5,472 $ 2,357 $ 3,162 $ 5,519 1 Renal Care includes sales of our peritoneal dialysis (PD), hemodialysis (HD) and additional dialysis therapies and services. 2 Medication Delivery includes sales of our IV therapies, infusion pumps, administration sets and drug reconstitution devices. 3 Pharmaceuticals includes sales of our premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services. 4 Clinical Nutrition includes sales of our parenteral nutrition (PN) therapies and related products. 5 Advanced Surgery includes sales of our biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention. 6 Acute Therapies includes sales of our continuous renal replacement therapies (CRRT) and other organ support therapies focused in the intensive care unit (ICU). 7 Other primarily includes sales of contract manufacturing services from our pharmaceutical partnering business.

BUSINESS OPTIMIZATION CHARGES (

BUSINESS OPTIMIZATION CHARGES (Tables)	6 Months Ended
	Jun. 30, 2019
Restructuring And Related Activities [Abstract]
Summary of Business Optimization Charges	During the three and six months ended June 30, 2019 and 2018, we recorded the following charges related to business optimization programs. Three months ended Six months ended June 30, June 30, (in millions) 2019 2018 2019 2018 Restructuring charges $ 52 $ 21 $ 77 $ 33 Costs to implement business optimization programs 12 25 22 50 Accelerated depreciation 1 1 4 2 Total business optimization charges $ 65 $ 47 $ 103 $ 85
Components of Restructuring Charges	During the three and six months ended June 30, 2019 and 2018, we recorded the following restructuring charges. Three months ended June 30, 2019 (in millions) COGS SG&A R&D Total Employee termination costs $ 6 $ 26 $ 17 $ 49 Contract termination and other costs 1 — — 1 Asset impairments 1 — 1 2 Total restructuring charges $ 8 $ 26 $ 18 $ 52 Three months ended June 30, 2018 (in millions) COGS SG&A R&D Total Employee termination costs $ 3 $ 8 $ 7 $ 18 Contract termination costs — 2 — 2 Asset impairments — 1 — 1 Total restructuring charges $ 3 $ 11 $ 7 $ 21 Six months ended June 30, 2019 (in millions) COGS SG&A R&D Total Employee termination costs $ 6 $ 25 $ 26 $ 57 Contract termination and other costs 8 — — 8 Asset impairments 10 1 1 12 Total restructuring charges $ 24 $ 26 $ 27 $ 77 Six months ended June 30, 2018 (in millions) COGS SG&A R&D Total Employee termination costs $ 4 $ 14 $ 10 $ 28 Contract termination costs — 2 — 2 Asset impairments 1 2 — 3 Total restructuring charges $ 5 $ 18 $ 10 $ 33
Summary of Activity in Reserves Related to Restructuring Initiatives	The following table summarizes activity in the reserves related to our restructuring initiatives. (in millions) Reserve as of December 31, 2018 $ 101 Charges 78 Reserve adjustments (13 ) Utilization (60 ) Currency translation 2 Reserve as of June 30, 2019 $ 108

PENSION AND OTHER POSTRETIREM_2

PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS (Tables)	6 Months Ended
	Jun. 30, 2019
Compensation And Retirement Disclosure [Abstract]
Net Periodic Benefit Cost Relating to Pension and Other Postemployment Employee Benefit Plans	The following is a summary of net periodic benefit cost relating to our pension and OPEB plans. Three months ended Six months ended June 30, June 30, (in millions) 2019 2018 2019 2018 Pension benefits Service cost $ 19 $ 25 $ 38 $ 47 Interest cost 43 45 90 91 Expected return on plan assets (67 ) (79 ) (140 ) (157 ) Amortization of net losses and prior service costs 14 24 29 48 Net periodic pension benefit cost $ 9 $ 15 $ 17 $ 29 OPEB Interest cost $ 2 $ 2 $ 4 $ 4 Amortization of net loss and prior service credit (7 ) (6 ) (14 ) (12 ) Net periodic OPEB cost $ (5 ) $ (4 ) $ (10 ) $ (8 )

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
Reconciliation of Basic Shares to Diluted Shares	The following table is a reconciliation of basic shares to diluted shares. Three months ended Six months ended June 30, June 30, (in millions) 2019 2018 2019 2018 Basic shares 510 535 511 537 Effect of dilutive securities 9 12 9 12 Diluted shares 519 547 520 549

DERIVATIVE INSTRUMENTS AND HE_2

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)	6 Months Ended
	Jun. 30, 2019
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Summary of Gains and Losses on Derivative Instruments	The following tables summarize the income statement locations and gains and losses on our derivative instruments for the three months ended June 30, 2019 and 2018. Gain (loss) recognized in OCI Location of gain (loss) Gain (loss) reclassified from AOCI into income (in millions) 2019 2018 in income statement 2019 2018 Cash flow hedges Interest rate contracts $ (23 ) $ — Interest expense, net $ — $ — Foreign exchange contracts 9 7 Cost of sales 1 (6 ) Net investment hedges (36 ) 38 Other income, net — — Total $ (50 ) $ 45 $ 1 $ (6 ) Gain (loss) recognized in income (in millions) Location of gain (loss) in income statement 2019 2018 Undesignated derivative instruments Foreign exchange contracts Other income, net $ 3 $ 6 The following tables summarize the income statement locations and gains and losses on our derivative instruments for the six months ended June 30, 2019 and 2018. Gain (loss) recognized in OCI Location of gain (loss) Gain (loss) reclassified from AOCI into income (in millions) 2019 2018 in income statement 2019 2018 Cash flow hedges Interest rate contracts $ (34 ) $ — Interest expense, net $ — $ — Foreign exchange contracts — (2 ) Cost of sales 1 (10 ) Net investment hedges (22 ) 17 Other income, net — — Total $ (56 ) $ 15 $ 1 $ (10 ) Gain (loss) recognized in income (in millions) Location of gain (loss) in income statement 2019 2018 Fair value hedges Interest rate contracts Interest expense, net $ — $ (4 ) Undesignated derivative instruments Foreign exchange contracts Other income, net $ (6 ) $ (11 )
Classification and Fair Values of Derivative Instruments	The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of June 30, 2019. Derivatives in asset positions Derivatives in liability positions (in millions) Balance sheet location Fair value Balance sheet location Fair value Derivative instruments designated as hedges Interest rate contracts Other non-current assets $ — Other non-current liabilities $ 37 Foreign exchange contracts Prepaid expenses and other 20 Accounts payable and accrued liabilities 1 Foreign exchange contracts Other non-current assets 1 Other non-current liabilities — Total derivative instruments designated as hedges 21 38 Undesignated derivative instruments Foreign exchange contracts Prepaid expenses and other — Accounts payable and accrued liabilities — Total derivative instruments $ 21 $ 38 The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of December 31, 2018. Derivatives in asset positions Derivatives in liability positions (in millions) Balance sheet location Fair value Balance sheet location Fair value Derivative instruments designated as hedges Interest rate contracts Other non-current assets $ — Other non-current liabilities $ 3 Foreign exchange contracts Prepaid expenses and other 22 Accounts payable and accrued liabilities 1 Foreign exchange contracts Other non-current assets 1 Other non-current liabilities — Total derivative instruments designated as hedges 23 4 Undesignated derivative instruments Foreign exchange contracts Prepaid expenses and other — Accounts payable and accrued liabilities 1 Total derivative instruments $ 23 $ 5
Derivative Positions Presented On Net Basis	The following table provides information on our derivative positions as if they were presented on a net basis, allowing for the right of offset by counterparty. June 30, 2019 December 31, 2018 (in millions) Asset Liability Asset Liability Gross amounts recognized in the consolidated balance sheet $ 21 $ 38 $ 23 $ 5 Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet (1 ) (1 ) (5 ) (5 ) Total $ 20 $ 37 $ 18 $ —
Amounts Recorded on Condensed Consolidated Balance Sheet Related to Fair Value Hedges	The following table presents the amounts recorded on the condensed consolidated balance sheet related to fair value hedges: Carrying amount of hedged item Cumulative amount of fair value hedging adjustment included in the carrying amount of the hedged item (a) (in millions) Balance as of June 30, 2019 Balance as of December 31, 2018 Balance as of June 30, 2019 Balance as of December 31, 2018 Long-term debt $ 103 $ 103 $ 6 $ 7 (a) These fair value hedges were terminated prior to December 31, 2018.

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Summary of Financial Instruments Measured at Fair Value on Recurring Basis	The following tables summarize our financial instruments that are measured at fair value on a recurring basis. Basis of fair value measurement (in millions) Balance as of June 30, 2019 Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Assets Foreign exchange contracts $ 21 $ — $ 21 $ — Marketable equity securities 4 4 — — Total $ 25 $ 4 $ 21 $ — Liabilities Foreign exchange contracts $ 1 $ — $ 1 $ — Interest rate contracts 37 — 37 — Contingent payments related to acquisitions 27 — — 27 Total $ 65 $ — $ 38 $ 27 Basis of fair value measurement (in millions) Balance as of December 31, 2018 Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Assets Foreign exchange contracts $ 23 $ — $ 23 $ — Marketable equity securities 3 3 — — Total $ 26 $ 3 $ 23 $ — Liabilities Foreign exchange contracts $ 2 $ — $ 2 $ — Interest rate contracts 3 — 3 — Contingent payments related to acquisitions 32 — — 32 Total $ 37 $ — $ 5 $ 32
Reconciliation of Fair Value Measurements that Use Significant Unobservable Inputs	The following table is a reconciliation of the fair value measurements that use significant unobservable inputs (Level 3), which consist of contingent payments related to acquisitions. Three months ended June 30, Six months ended June 30, (in millions) 2019 2018 2019 2018 Fair value at beginning of period $ 31 $ 23 $ 32 $ 9 Additions — — — 14 Change in fair value recognized in earnings (4 ) — (4 ) — Payments — — (1 ) — Fair value at end of period $ 27 $ 23 $ 27 $ 23
Book Values and Fair Values of Financial Instruments	the following table provides the values recognized in the condensed consolidated balance sheets and the estimated fair values as of June 30, 2019 and December 31, 2018. Book values Fair values (a) (in millions) 2019 2018 2019 2018 Liabilities Short-term debt $ 2 $ 2 $ 2 $ 2 Current maturities of long-term debt and finance lease obligations 2 2 2 2 Long-term debt and finance lease obligations 5,157 3,473 5,440 3,460 (a) These fair value amounts are classified as Level 2 within the fair value hierarchy as they are estimated based on observable inputs.

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2019
Segment Reporting [Abstract]
Summary of Financial Information for Our Segments	Financial information for our segments is as follows. Three months ended Six months ended June 30, June 30, (in millions) 2019 2018 2019 2018 Net sales Americas $ 1,520 $ 1,525 $ 2,928 $ 2,967 EMEA 744 758 1,449 1,482 APAC 576 559 1,095 1,070 Total net sales $ 2,840 $ 2,842 $ 5,472 $ 5,519 Operating Income Americas $ 584 $ 619 $ 1,121 $ 1,185 EMEA 162 162 307 313 APAC 137 131 258 248 Total segment operating income $ 883 $ 912 $ 1,686 $ 1,746
Operating Income to Income Before Income Taxes Reconciliation	The following is a reconciliation of segment operating income to income before income taxes per the condensed consolidated statements of income. Three months ended Six months ended June 30, June 30, (in millions) 2019 2018 2019 2018 Total segment operating income $ 883 $ 912 $ 1,686 $ 1,746 Corporate and other (528 ) (528 ) (947 ) (930 ) Total operating income 355 384 739 816 Net interest expense 20 11 38 23 Other income, net (28 ) (31 ) (53 ) (49 ) Income before income taxes $ 363 $ 404 $ 754 $ 842

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Detail) - USD ($) $ in Millions	Jan. 01, 2019	Jun. 30, 2019
Disclosure Basis Of Presentation Details [Line Items]
Operating lease right-of-use asset		$ 588
Operating lease liabilities		490
ASU 2016-02 | Adjustment
Disclosure Basis Of Presentation Details [Line Items]
Operating lease right-of-use asset	$ 502
Operating lease liabilities	502
ASU 2018-02
Disclosure Basis Of Presentation Details [Line Items]
Other comprehensive income to retained earnings	$ 161	$ 161

Acquisitions and Other Arrang_2

Acquisitions and Other Arrangements - Additional Information (Detail) - USD ($) $ in Millions	Jul. 30, 2019	Mar. 31, 2019
Subsequent Event
Acquisitions And Collaborations [Line Items]
Payments to acquire rights	$ 62
Weighted-average useful life	12 years
U.S. Rights to Multiple Products
Acquisitions And Collaborations [Line Items]
Payments to acquire rights		$ 94
Weighted-average useful life		10 years

Supplemental Financial Inform_3

Supplemental Financial Information - Interest Expense, Net (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Interest Income Expense Net
Interest expense, net of capitalized interest	$ 28	$ 24	$ 53	$ 46
Interest income	(8)	(13)	(15)	(23)
Interest expense, net	$ 20	$ 11	$ 38	$ 23

Supplemental Financial Inform_4

Supplemental Financial Information - Other Income, Net (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Other Income, net
Foreign exchange gains, net	$ (17)	$ (18)	$ (22)	$ (33)
Pension and other postretirement benefits	(15)	(14)	(31)	(26)
Other	4	1		10
Other income, net	$ (28)	$ (31)	$ (53)	$ (49)

Supplemental Financial Inform_5

Supplemental Financial Information - Inventories (Detail) - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 397	$ 363
Work in process	197	203
Finished goods	1,163	1,087
Inventories	$ 1,757	$ 1,653

Supplemental Financial Inform_6

Supplemental Financial Information - Property, Plant and Equipment, Net (Detail) - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018
Property, Plant and Equipment, Net
Property, plant and equipment, at cost	$ 10,593	$ 10,327
Accumulated depreciation	(6,052)	(5,785)
Property, plant and equipment, net	$ 4,541	$ 4,542

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets, Net - Goodwill (Detail) $ in Millions	6 Months Ended
	Jun. 30, 2019USD ($)
Goodwill [Line Items]
Goodwill, beginning balance	$ 2,958
Adjustments	(4)
Currency translation adjustments	(16)
Goodwill, ending balance	2,938
Americas
Goodwill [Line Items]
Goodwill, beginning balance	2,351
Currency translation adjustments	(13)
Goodwill, ending balance	2,338
EMEA
Goodwill [Line Items]
Goodwill, beginning balance	387
Adjustments	(4)
Currency translation adjustments	(2)
Goodwill, ending balance	381
APAC
Goodwill [Line Items]
Goodwill, beginning balance	220
Currency translation adjustments	(1)
Goodwill, ending balance	$ 219

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets, Net - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Goodwill And Other Intangible Asset [Line Items]
Accumulated goodwill impairment losses	$ 0		$ 0
Intangible asset amortization expense	45,000,000	$ 44,000,000	88,000,000	$ 85,000,000
Impairment of intangible assets			31,000,000
Developed Technology Intangible Asset
Goodwill And Other Intangible Asset [Line Items]
Impairment of intangible assets	$ 31,000,000		$ 31,000,000

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets, Net - Other Intangible Assets, Net (Detail) - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018
Intangible Asset Excluding Goodwill [Line Items]
Gross other intangible assets	$ 2,802	$ 2,754
Accumulated amortization	(1,438)	(1,356)
Other intangible assets, net	1,364	1,398
Developed technology, including patents
Intangible Asset Excluding Goodwill [Line Items]
Gross other intangible assets	2,164	2,115
Accumulated amortization	(1,171)	(1,106)
Other intangible assets, net	993	1,009
Other amortized intangible assets
Intangible Asset Excluding Goodwill [Line Items]
Gross other intangible assets	450	451
Accumulated amortization	(267)	(250)
Other intangible assets, net	183	201
Indefinite-lived intangible assets
Intangible Asset Excluding Goodwill [Line Items]
Other intangible assets	$ 188	$ 188

Financing Arrangements - Additi

Financing Arrangements - Additional Information (Detail) € in Millions	1 Months Ended	3 Months Ended	6 Months Ended
	May 31, 2019EUR (€)	Jun. 30, 2019USD ($)	Jun. 30, 2019USD ($)	Dec. 31, 2018USD ($)
Debt Instrument [Line Items]
Repayments of outstanding commercial paper and other short-term borrowings | $		$ 795,000,000
Commercial paper | $		$ 0	$ 0	$ 0
0.4% Senior Notes Due in May 2024
Debt Instrument [Line Items]
Senior notes | €	€ 750
Higher rate of debt maturity periods	May 2024		May 2024
Senior notes, interest rate	0.40%
1.3% Senior Notes Due in May 2029
Debt Instrument [Line Items]
Senior notes | €	€ 750
Higher rate of debt maturity periods	May 2029		May 2029
Senior notes, interest rate	1.30%

Leases - Additional Information

Leases - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2019
Leases [Line Items]
Lessee, option to extend lease, description	Our leases have remaining terms from one to 25 years and some of those leases include options that provide us with the ability to extend the lease term for periods ranging from one to 12 years.
Lessee, existence of option to extend lease	true
Lessor, option to extend lease, description	The terms of the related contracts, including the proportion of fixed versus variable payments and any options to shorten or extend the lease term, vary by customer.
Lessor, existence of option to extend lease	true
Minimum
Leases [Line Items]
Remaining term of contract	1 year
Lessee, option to extend lease term	1 year
Maximum
Leases [Line Items]
Remaining term of contract	25 years
Lessee, option to extend lease term	12 years

Leases - Components of Lease Co

Leases - Components of Lease Cost (Detail) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019
Leases [Abstract]
Operating lease cost	$ 29	$ 60
Finance lease cost
Amortization of right-of-use assets	1	2
Interest on lease liabilities		1
Variable lease cost	21	43
Lease cost	$ 51	$ 106

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information Related to Leases (Detail) $ in Millions	6 Months Ended
	Jun. 30, 2019USD ($)
Leases [Abstract]
Operating cash flows from operating leases	$ 60
Operating cash flows from finance leases	3
Financing cash flows from finance leases	1
Right-of-use operating lease assets obtained in exchange for lease obligations	$ 140

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information Related to Leases (Detail) $ in Millions	Jun. 30, 2019USD ($)
Leases [Abstract]
Operating lease right-of-use assets	$ 588
Current operating lease liabilities	$ 98
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
Operating lease liabilities	$ 490
Total operating lease liabilities	588
Property, plant and equipment, at cost	81
Accumulated depreciation	(27)
Property, plant and equipment, net	54
Current maturities of long-term debt and finance lease obligations	$ 1
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	bax:CurrentMaturitiesOfLongTermDebtAndFinanceLeaseObligations
Long-term debt and finance lease obligations	$ 58
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	bax:LongTermDebtAndFinanceLeaseObligationsNoncurrent
Total finance lease liabilities	$ 59

Leases - Schedule of Lease Term

Leases - Schedule of Lease Term and Discount Rates (Detail)	Jun. 30, 2019
Leases [Abstract]
Operating leases, Weighted-average remaining lease term (years)	10 years
Finance leases, Weighted-average remaining lease term (years)	15 years
Operating leases, Weighted-average discount rate	2.80%
Finance leases, Weighted-average discount rate	10.30%

Leases - Maturities of Operatin

Leases - Maturities of Operating and Finance Lease Liabilities (Detail) $ in Millions	Jun. 30, 2019USD ($)
Finance Leases
2019	$ 4
2020	8
2021	8
2022	8
2023	6
Thereafter	82
Total minimum lease payments	116
Less: imputed interest	(57)
Present value of lease liabilities	59
Operating Leases
2019	59
2020	99
2021	83
2022	70
2023	59
Thereafter	297
Total minimum lease payments	667
Less: imputed interest	(79)
Present value of lease liabilities	$ 588

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Lease Payments (Detail) $ in Millions	Dec. 31, 2018USD ($)
Capital Leases
2019	$ 8
2020	7
2021	7
2022	8
2023	6
Thereafter	88
Total minimum lease payments	124
Less: imputed interest	(62)
Present value of lease liabilities	62
Operating Leases
2019	122
2020	93
2021	86
2022	71
2023	64
Thereafter	210
Total minimum lease payments	$ 646

Leases - Components of Lease Re

Leases - Components of Lease Revenue (Detail) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019
Leases [Abstract]
Sales-type lease revenue	$ 5	$ 11
Operating lease revenue	15	30
Variable lease revenue	21	42
Total lease revenue	$ 41	$ 83

Leases - Components of Net Inve

Leases - Components of Net Investment in Sales-type Lease (Detail) $ in Millions	Jun. 30, 2019USD ($)
Leases [Abstract]
Minimum lease payments	$ 86
Unguaranteed residual values	11
Net investment in leases	$ 97

Leases - Net Investment in Sale

Leases - Net Investment in Sales Type Leases Classified in Accompanying Condensed Consolidated Balance Sheets (Detail) $ in Millions	Jun. 30, 2019USD ($)
Leases [Abstract]
Accounts and other current receivables, net	$ 36
Other non-current assets	61
Total	$ 97

Leases - Maturities of Sales-ty

Leases - Maturities of Sales-type and Operating Leases (Detail) $ in Millions	Jun. 30, 2019USD ($)
Sales-type Leases
2019	$ 17
2020	30
2021	24
2022	15
2023	8
Thereafter	2
Total minimum lease payments	96
Less: imputed interest	(10)
Present value of minimum lease payments	86
Operating Leases
2019	24
2020	48
2021	48
2022	30
2023	16
Thereafter	7
Total minimum lease payments	$ 173

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	6 Months Ended	12 Months Ended
	Jun. 30, 2019USD ($)SiteLawsuit	Dec. 31, 2018USD ($)	Jul. 31, 2019USD ($)
Loss Contingencies [Line Items]
Litigation reserve	$ 49,000,000	$ 43,000,000
Litigation related receivables	0	0
Proceeds from insurance dispute settlements	35,000,000
Gain on insurance claims	$ 33,000,000
Hurricane Maria
Loss Contingencies [Line Items]
Insurance recoveries		42,000,000
Hurricane Maria | Subsequent Event
Loss Contingencies [Line Items]
Insurance recoveries yet to be recognized			$ 40,000,000
Minimum
Loss Contingencies [Line Items]
Number of law suits filed | Lawsuit	1,000
Superfund Sites | Environmental Clean-up
Loss Contingencies [Line Items]
Number of sites | Site	6
Name of site	Superfund
Environmental reserves	$ 20,000,000	$ 19,000,000

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	May 07, 2019	Dec. 31, 2018	Nov. 30, 2018	Feb. 28, 2018	Nov. 30, 2016	Jul. 31, 2012
Stockholders Equity Note [Line Items]
Cash dividends declared per common share	$ 0.22	$ 0.19	$ 0.41	$ 0.35
Stock repurchase program, authorized amount										$ 2,000,000,000
Stock repurchase program, additional authorized amount							$ 2,000,000,000	$ 1,500,000,000	$ 1,500,000,000
Share repurchases			9,500,000	11,500,000
Remaining value available under stock repurchase programs	$ 1,400,000,000		$ 1,400,000,000
ASR Agreement
Stockholders Equity Note [Line Items]
Stock repurchase program, authorized amount						$ 300,000,000
Stock repurchase program, authorized to be purchased					600,000	3,600,000

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income - Summary of Changes in AOCI by Component (Detail) - USD ($) $ in Millions		Jan. 01, 2019	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning of period		$ 7,816	$ 7,669	$ 7,816	$ 9,093	$ 9,116	$ 7,816	$ 9,116
Other comprehensive income before reclassifications							(66)	(232)
Amounts reclassified from AOCI	[1]						12	37
Total other comprehensive (loss) income, net of tax			(77)	23	(323)	128	(54)	(195)
End of period			7,836	7,669	8,869	9,093	7,836	8,869
ASU 2018-02
Accumulated Other Comprehensive Income (Loss) [Line Items]
Adoption of new accounting standard		(161)					(161)
ASU 2016-01
Accumulated Other Comprehensive Income (Loss) [Line Items]
Adoption of new accounting standard								(3)
CTA
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning of period		(3,474)		(3,474)		(3,013)	(3,474)	(3,013)
Other comprehensive income before reclassifications							(48)	(282)
Total other comprehensive (loss) income, net of tax							(48)	(282)
End of period			(3,513)		(3,295)		(3,513)	(3,295)
CTA | ASU 2018-02
Accumulated Other Comprehensive Income (Loss) [Line Items]
Adoption of new accounting standard							9
Pension and OPEB Plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning of period		(949)		(949)		(981)	(949)	(981)
Other comprehensive income before reclassifications							8	51
Amounts reclassified from AOCI	[1]						13	30
Total other comprehensive (loss) income, net of tax							21	81
End of period			(1,097)		(900)		(1,097)	(900)
Pension and OPEB Plans | ASU 2018-02
Accumulated Other Comprehensive Income (Loss) [Line Items]
Adoption of new accounting standard							(169)
Hedging activities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning of period		(1)		(1)		(10)	(1)	(10)
Other comprehensive income before reclassifications							(26)	(1)
Amounts reclassified from AOCI	[1]						(1)	7
Total other comprehensive (loss) income, net of tax							(27)	6
End of period			(29)		(4)		(29)	(4)
Hedging activities | ASU 2018-02
Accumulated Other Comprehensive Income (Loss) [Line Items]
Adoption of new accounting standard							(1)
Available-for-sale securities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning of period						3		3
Available-for-sale securities | ASU 2016-01
Accumulated Other Comprehensive Income (Loss) [Line Items]
Adoption of new accounting standard								(3)
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning of period		$ (4,424)		$ (4,424)		$ (4,001)	(4,424)	(4,001)
End of period			$ (4,639)		$ (4,199)		$ (4,639)	$ (4,199)
[1]	Amounts in parentheses indicate reductions to net income.

Accumulated Other Comprehensi_4

Accumulated Other Comprehensive Income - Summary of Amounts Reclassification from AOCI to Net Income (Detail) - USD ($) $ in Millions		3 Months Ended				6 Months Ended
		Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other income, net		$ 28		$ 31		$ 53	$ 49
Total before tax		363		404		754	842
Income tax expense		20		61		64	110
Net income		343	$ 347	343	$ 389	690	732
Cost of sales		1,681		1,603		3,233	3,166
Amounts reclassified from AOCI
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net income	[1]	(5)		(19)		(12)	(37)
Amortization of pension and OPEB items | Amounts reclassified from AOCI
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other income, net	[1]	(7)		(18)		(15)	(36)
Total before tax	[1]	(7)		(18)		(15)	(36)
Income tax expense	[1]	1		3		2	6
Net income	[1]	(6)		(15)		(13)	(30)
Gains (losses) on hedging activities | Amounts reclassified from AOCI
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total before tax	[1]	1		(6)		1	(10)
Income tax expense	[1]			2			3
Net income	[1]	1		(4)		1	(7)
Gains (losses) on hedging activities | Foreign exchange contract | Amounts reclassified from AOCI
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Cost of sales	[1]	$ 1		$ (6)		$ 1	$ (10)
[1]	Amounts in parentheses indicate reductions to net income.

Revenues - Additional Informati

Revenues - Additional Information (Detail) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Revenue From Contract With Customer [Line Items]
Transaction price allocated to remaining performance obligations	$ 8,900
Net trade accounts receivable	1,800	$ 1,700
Contract assets	89	80
Accounts and Other Receivables, Net
Revenue From Contract With Customer [Line Items]
Contract assets	57	50
Other Non Current Assets
Revenue From Contract With Customer [Line Items]
Contract assets	32	30
Manufacturing Arrangements
Revenue From Contract With Customer [Line Items]
Contract assets	37	33
Software Arrangements
Revenue From Contract With Customer [Line Items]
Contract assets	40	$ 47
Bundled Equipment
Revenue From Contract With Customer [Line Items]
Contract assets	12
Consumable Medical Products
Revenue From Contract With Customer [Line Items]
Contract assets	$ 12
Maximum | Manufacturing Arrangements
Revenue From Contract With Customer [Line Items]
Revenue recognized contract period	90 days
Maximum | Software Arrangements
Revenue From Contract With Customer [Line Items]
Revenue recognized contract period	5 years
Maximum | Consumable Medical Products
Revenue From Contract With Customer [Line Items]
Revenue recognized contract period	7 years
Minimum | Software Arrangements
Revenue From Contract With Customer [Line Items]
Revenue recognized contract period	1 year
Minimum | Consumable Medical Products
Revenue From Contract With Customer [Line Items]
Revenue recognized contract period	1 year

Revenues - Additional Informa_2

Revenues - Additional Information1 (Detail)	Jun. 30, 2019
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2019-07-01
Revenue From Contract With Customer [Line Items]
Remaining revenue performance obligation, percentage of revenue expected to be recognized	10.00%
Remaining performance obligations period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2020-01-01
Revenue From Contract With Customer [Line Items]
Remaining revenue performance obligation, percentage of revenue expected to be recognized	20.00%
Remaining performance obligations period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2021-01-01
Revenue From Contract With Customer [Line Items]
Remaining revenue performance obligation, percentage of revenue expected to be recognized	20.00%
Remaining performance obligations period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-01-01
Revenue From Contract With Customer [Line Items]
Remaining revenue performance obligation, percentage of revenue expected to be recognized	20.00%
Remaining performance obligations period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2023-01-01
Revenue From Contract With Customer [Line Items]
Remaining revenue performance obligation, percentage of revenue expected to be recognized	10.00%
Remaining performance obligations period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2024-01-01
Revenue From Contract With Customer [Line Items]
Remaining revenue performance obligation, percentage of revenue expected to be recognized	10.00%
Remaining performance obligations period	1 year

Revenues - Net Sales from Contr

Revenues - Net Sales from Contracts with Customers by Global Business Unit (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenue From Contract With Customer [Line Items]
Net sales		$ 2,840	$ 2,842	$ 5,472	$ 5,519
U.S.
Revenue From Contract With Customer [Line Items]
Net sales		1,193	1,210	2,313	2,357
International
Revenue From Contract With Customer [Line Items]
Net sales		1,647	1,632	3,159	3,162
Renal
Revenue From Contract With Customer [Line Items]
Net sales	[1]	910	931	1,761	1,799
Renal | U.S.
Revenue From Contract With Customer [Line Items]
Net sales	[1]	196	204	388	400
Renal | International
Revenue From Contract With Customer [Line Items]
Net sales	[1]	714	727	1,373	1,399
Medication Delivery
Revenue From Contract With Customer [Line Items]
Net sales	[2]	689	681	1,323	1,357
Medication Delivery | U.S.
Revenue From Contract With Customer [Line Items]
Net sales	[2]	441	426	847	862
Medication Delivery | International
Revenue From Contract With Customer [Line Items]
Net sales	[2]	248	255	476	495
Pharmaceuticals
Revenue From Contract With Customer [Line Items]
Net sales	[3]	539	537	1,048	1,033
Pharmaceuticals | U.S.
Revenue From Contract With Customer [Line Items]
Net sales	[3]	235	262	467	505
Pharmaceuticals | International
Revenue From Contract With Customer [Line Items]
Net sales	[3]	304	275	581	528
Clinical Nutrition
Revenue From Contract With Customer [Line Items]
Net sales	[4]	215	221	420	444
Clinical Nutrition | U.S.
Revenue From Contract With Customer [Line Items]
Net sales	[4]	79	80	156	163
Clinical Nutrition | International
Revenue From Contract With Customer [Line Items]
Net sales	[4]	136	141	264	281
Advanced Surgery
Revenue From Contract With Customer [Line Items]
Net sales	[5]	232	204	430	386
Advanced Surgery | U.S.
Revenue From Contract With Customer [Line Items]
Net sales	[5]	143	118	263	217
Advanced Surgery | International
Revenue From Contract With Customer [Line Items]
Net sales	[5]	89	86	167	169
Acute Therapies
Revenue From Contract With Customer [Line Items]
Net sales	[6]	133	129	261	258
Acute Therapies | U.S.
Revenue From Contract With Customer [Line Items]
Net sales	[6]	44	42	92	88
Acute Therapies | International
Revenue From Contract With Customer [Line Items]
Net sales	[6]	89	87	169	170
Other
Revenue From Contract With Customer [Line Items]
Net sales	[7]	122	139	229	242
Other | U.S.
Revenue From Contract With Customer [Line Items]
Net sales	[7]	55	78	100	122
Other | International
Revenue From Contract With Customer [Line Items]
Net sales	[7]	$ 67	$ 61	$ 129	$ 120
[1]	Renal Care includes sales of our peritoneal dialysis (PD), hemodialysis (HD) and additional dialysis therapies and services.
[2]	Medication Delivery includes sales of our IV therapies, infusion pumps, administration sets and drug reconstitution devices.
[3]	Pharmaceuticals includes sales of our premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services.
[4]	Clinical Nutrition includes sales of our parenteral nutrition (PN) therapies and related products.
[5]	Advanced Surgery includes sales of our biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention.
[6]	Acute Therapies includes sales of our continuous renal replacement therapies (CRRT) and other organ support therapies focused in the intensive care unit (ICU).
[7]	Other primarily includes sales of contract manufacturing services from our pharmaceutical partnering business.

Business Optimization Charges -

Business Optimization Charges - Additional Information (Detail) $ in Millions	Jun. 30, 2019USD ($)
Restructuring And Related Activities [Abstract]
Cumulative pre-tax costs incurred	$ 899
Expected additional pre-tax costs	$ 70

Business Optimization Charges_2

Business Optimization Charges - Summary of Business Optimization Charges (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Restructuring And Related Activities [Abstract]
Restructuring charges	$ 52	$ 21	$ 77	$ 33
Costs to implement business optimization programs	12	25	22	50
Accelerated depreciation	1	1	4	2
Total business optimization charges	$ 65	$ 47	$ 103	$ 85

Business Optimization Charges_3

Business Optimization Charges - Components of Restructuring Charges (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Restructuring Cost And Reserve [Line Items]
Restructuring charges	$ 52	$ 21	$ 77	$ 33
Cost of Goods Sold
Restructuring Cost And Reserve [Line Items]
Restructuring charges	8	3	24	5
Selling, General and Administrative Expenses
Restructuring Cost And Reserve [Line Items]
Restructuring charges	26	11	26	18
Research and Development Expenses
Restructuring Cost And Reserve [Line Items]
Restructuring charges	18	7	27	10
Employee Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	49	18	57	28
Employee Termination Costs | Cost of Goods Sold
Restructuring Cost And Reserve [Line Items]
Restructuring charges	6	3	6	4
Employee Termination Costs | Selling, General and Administrative Expenses
Restructuring Cost And Reserve [Line Items]
Restructuring charges	26	8	25	14
Employee Termination Costs | Research and Development Expenses
Restructuring Cost And Reserve [Line Items]
Restructuring charges	17	7	26	10
Contract Termination and Other Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	1		8
Contract Termination and Other Costs | Cost of Goods Sold
Restructuring Cost And Reserve [Line Items]
Restructuring charges	1		8
Asset Impairments
Restructuring Cost And Reserve [Line Items]
Restructuring charges	2	1	12	3
Asset Impairments | Cost of Goods Sold
Restructuring Cost And Reserve [Line Items]
Restructuring charges	1		10	1
Asset Impairments | Selling, General and Administrative Expenses
Restructuring Cost And Reserve [Line Items]
Restructuring charges		1	1	2
Asset Impairments | Research and Development Expenses
Restructuring Cost And Reserve [Line Items]
Restructuring charges	$ 1		$ 1
Contract Termination costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges		2		2
Contract Termination costs | Selling, General and Administrative Expenses
Restructuring Cost And Reserve [Line Items]
Restructuring charges		$ 2		$ 2

Business Optimization Charges_4

Business Optimization Charges - Summary of Activity in Reserves Related to Restructuring Initiatives (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Restructuring Cost And Reserve [Line Items]
Charges	$ 52	$ 21	$ 77	$ 33
Severance and Other Employee Related Costs
Restructuring Cost And Reserve [Line Items]
Reserve, beginning balance			101
Charges			78
Reserve adjustments			(13)
Utilization			(60)
Currency translation			2
Reserve, ending balance	$ 108		$ 108

Pension and Other Postretirem_3

Pension and Other Postretirement Benefit Programs - Net Periodic Benefit Cost Relating to Pension and Other Postemployment Employee Benefit Plans (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Pension benefits
Net periodic benefit cost
Service cost	$ 19	$ 25	$ 38	$ 47
Interest cost	43	45	90	91
Expected return on plan assets	(67)	(79)	(140)	(157)
Amortization of net losses and prior service costs (credit)	14	24	29	48
Net periodic cost	9	15	17	29
OPEB
Net periodic benefit cost
Interest cost	2	2	4	4
Amortization of net losses and prior service costs (credit)	(7)	(6)	(14)	(12)
Net periodic cost	$ (5)	$ (4)	$ (10)	$ (8)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Effective income tax rate	5.50%	15.10%	8.50%	13.10%
U.S. Federal statutory rate	21.00%	21.00%	21.00%	21.00%

Earnings Per Share - Reconcilia

Earnings Per Share - Reconciliation of Basic Shares to Diluted Shares (Detail) - shares shares in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Reconciliation of Basic Shares to Diluted Shares
Basic shares	510	535	511	537
Effect of dilutive securities	9	12	9	12
Diluted shares	519	547	520	549

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - shares shares in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Earnings Per Share [Abstract]
Anti-dilutive securities excluded from computation of EPS	4	4	4	3

Derivative Instruments and He_3

Derivative Instruments and Hedging Activities - Additional Information (Detail) € in Millions	1 Months Ended		3 Months Ended			6 Months Ended
	May 31, 2019EUR (€)	May 31, 2017EUR (€)	Jun. 30, 2019USD ($)	Jun. 30, 2019EUR (€)	Jun. 30, 2018USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Dec. 31, 2018USD ($)
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Forward contracts designated as net investment hedge			$ (78,000,000)		$ (363,000,000)	$ (48,000,000)	$ (282,000,000)
Terminated fair value hedges						0	0
Gain (loss) on hedged item in fair value hedge					4,000,000		4,000,000
Deferred, net after-tax gains on derivative instruments						13,000,000
Designated as Hedging Instrument
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative notional amount			0		$ 0	0	$ 0
Not Designated as Hedging Instrument
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative notional amount			494,000,000			$ 494,000,000		$ 485,000,000
1.30% Senior Notes due May 2025
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Senior notes | €		€ 600
Higher rate of debt maturity periods		May 2025
0.4% Senior Notes Due in May 2024
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Senior notes | €	€ 750
Higher rate of debt maturity periods	May 2024					May 2024
1.3% Senior Notes Due in May 2029
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Senior notes | €	€ 750
Higher rate of debt maturity periods	May 2029					May 2029
Net investment hedge
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Accumulated pre-tax unrealized translation losses in AOCI related to euro-denominated senior notes			69,000,000			$ 69,000,000
Net investment hedge | Forward Contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Forward contracts designated as net investment hedge | €				€ 1,200
Net investment hedge | Designated as Hedging Instrument | Forward Contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Forward contracts designated as net investment hedge | €	€ 1,200
Foreign exchange contract
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative notional amount			629,000,000			$ 629,000,000		775,000,000
Maximum length of time hedge in cash flow hedge						18 months
Interest rate contract
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative notional amount			300,000,000			$ 300,000,000		150,000,000
Maximum length of time hedge in cash flow hedge						30 years
Interest rate contract | Fair value hedges
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative notional amount			$ 0			$ 0		$ 0

Derivative Instruments and He_4

Derivative Instruments and Hedging Activities - Summary of Gains and Losses on Derivative Instruments (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in OCI	$ (50)	$ 45	$ (56)	$ 15
Gains (losses) on hedging activities reclassified from AOCI to net income, before tax	1	(6)	1	(10)
Gain (loss) recognized in income, fair value hedges		4		4
Other income, net | Undesignated Derivative Instruments
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in income, undesignated derivative instruments	3	6	(6)	(11)
Cash Flow Hedges | Interest rate contract
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in OCI	(23)		(34)
Cash Flow Hedges | Foreign exchange contract
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in OCI	9	7		(2)
Cash Flow Hedges | Foreign exchange contract | Cost of Sales
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) on hedging activities reclassified from AOCI to net income, before tax	1	(6)	1	(10)
Net investment hedges
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in OCI	$ (36)	$ 38	$ (22)	17
Fair value hedges | Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in income, fair value hedges				$ (4)

Derivative Instruments and He_5

Derivative Instruments and Hedging Activities - Classification and Fair Value Amounts of Derivative Instruments (Detail) - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018
Derivatives, Fair Value [Line Items]
Derivative asset, fair value	$ 21	$ 23
Derivative liability, fair value	38	5
Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Derivative asset, fair value	21	23
Derivative liability, fair value	38	4
Designated as Hedging Instrument | Interest rate contract | Other Non-current Liabilities
Derivatives, Fair Value [Line Items]
Derivative liability, fair value	37	3
Designated as Hedging Instrument | Foreign exchange contract | Other Non-current Assets
Derivatives, Fair Value [Line Items]
Derivative asset, fair value	1	1
Designated as Hedging Instrument | Foreign exchange contract | Prepaid expenses and other
Derivatives, Fair Value [Line Items]
Derivative asset, fair value	20	22
Designated as Hedging Instrument | Foreign exchange contract | Accounts Payable And Accrued Liabilities
Derivatives, Fair Value [Line Items]
Derivative liability, fair value	$ 1	1
Undesignated Derivative Instruments | Foreign exchange contract | Accounts Payable And Accrued Liabilities
Derivatives, Fair Value [Line Items]
Derivative liability, fair value		$ 1

Derivative Instruments and He_6

Derivative Instruments and Hedging Activities - Derivative Positions Presented On Net Basis (Detail) - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Gross amounts recognized in the consolidated balance sheet, Asset	$ 21	$ 23
Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, Asset	(1)	(5)
Total, Asset	20	18
Gross amounts recognized in the consolidated balance sheet, Liability	38	5
Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, Liability	(1)	$ (5)
Total, Liability	$ 37

Derivative Instruments and He_7

Derivative Instruments and Hedging Activities - Amounts Recorded on Condensed Consolidated Balance Sheet Related to Fair Value Hedges (Detail) - Long-term debt - USD ($) $ in Millions		Jun. 30, 2019	Dec. 31, 2018
Derivatives, Fair Value [Line Items]
Carrying amount of hedged item		$ 103	$ 103
Cumulative amount of fair value hedging adjustment included in the carrying amount of the hedged item	[1]	$ 6	$ 7
[1]	These fair value hedges were terminated prior to December 31, 2018.

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Foreign exchange contracts, assets at fair value	$ 21	$ 23
Marketable equity securities	4	3
Total assets	25	26
Foreign currency hedges, liabilities at fair value	1	2
Interest rate contracts, liabilities at fair value	37	3
Contingent payments related to acquisitions	27	32
Total liabilities	65	37
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable equity securities	4	3
Total assets	4	3
Significant Other Observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Foreign exchange contracts, assets at fair value	21	23
Total assets	21	23
Foreign currency hedges, liabilities at fair value	1	2
Interest rate contracts, liabilities at fair value	37	3
Total liabilities	38	5
Significant Unobservable Inputs (Level 3)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent payments related to acquisitions	27	32
Total liabilities	$ 27	$ 32

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018
Fair Value Disclosures [Line Items]
Cash and cash equivalents	$ 2,925	$ 1,832
Other Assets
Fair Value Disclosures [Line Items]
Other equity investments without readily determinable fair values	39	41
Significant Other Observable Inputs (Level 2)
Fair Value Disclosures [Line Items]
Money market funds, at carrying value	$ 1.5	$ 169

Fair Value Measurements - Recon

Fair Value Measurements - Reconciliation of Fair Value Measurements that Use Significant Unobservable Inputs (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Fair Value Disclosures [Abstract]
Contingent payments, Fair value as of beginning of period	$ 31	$ 23	$ 32	$ 9
Contingent payments, additions	0	0	0	14
Contingent payments, change in fair value recognized in earnings	(4)	0	(4)	0
Contingent payments, payments	0	0	(1)	0
Contingent payments, Fair value as of end of period	$ 27	$ 23	$ 27	$ 23

Fair Value Measurements - Book

Fair Value Measurements - Book Values and Fair Values of Financial Instruments (Detail) - USD ($) $ in Millions		Jun. 30, 2019	Dec. 31, 2018
Book Values
Fair Value And Carrying Value By Balance Sheet Grouping [Line Items]
Short-term debt		$ 2	$ 2
Current maturities of long-term debt and finance lease obligations		2	2
Long-term debt and finance lease obligations		5,157	3,473
Fair values
Fair Value And Carrying Value By Balance Sheet Grouping [Line Items]
Short-term debt	[1]	2	2
Current maturities of long-term debt and finance lease obligations	[1]	2	2
Long-term debt and finance lease obligations	[1]	$ 5,440	$ 3,460
[1]	(a) These fair value amounts are classified as Level 2 within the fair value hierarchy as they are estimated based on observable inputs.

Segment Information - Summary o

Segment Information - Summary of Financial Information for Our Segments (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Segment Reporting Information [Line Items]
Net sales	$ 2,840	$ 2,842	$ 5,472	$ 5,519
Total segment operating income	355	384	739	816
Americas
Segment Reporting Information [Line Items]
Net sales	1,520	1,525	2,928	2,967
EMEA
Segment Reporting Information [Line Items]
Net sales	744	758	1,449	1,482
APAC
Segment Reporting Information [Line Items]
Net sales	576	559	1,095	1,070
Operating Segments
Segment Reporting Information [Line Items]
Total segment operating income	883	912	1,686	1,746
Operating Segments | Americas
Segment Reporting Information [Line Items]
Total segment operating income	584	619	1,121	1,185
Operating Segments | EMEA
Segment Reporting Information [Line Items]
Total segment operating income	162	162	307	313
Operating Segments | APAC
Segment Reporting Information [Line Items]
Total segment operating income	$ 137	$ 131	$ 258	$ 248

Segment Information - Operating

Segment Information - Operating Income to Income Before Income Taxes Reconciliation (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating income	$ 355	$ 384	$ 739	$ 816
Net interest expense	20	11	38	23
Other income, net	(28)	(31)	(53)	(49)
Income before income taxes	363	404	754	842
Operating Segments
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating income	883	912	1,686	1,746
Corporate and Other
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating income	$ (528)	$ (528)	$ (947)	$ (930)